MCID: BND020
MIFTS: 57

Bone Disease

Categories: Bone diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bone Disease

Summaries for Bone Disease

MedlinePlus: 41 Your bones help you move, give you shape and support your body. They are living tissues that rebuild constantly throughout your life. During childhood and your teens, your body adds new bone faster than it removes old bone. After about age 20, you can lose bone faster than you make bone. To have strong bones when you are young, and to prevent bone loss when you are older, you need to get enough calcium, vitamin D, and exercise. You should also avoid smoking and drinking too much alcohol. Bone diseases can make bones easy to break. Different kinds of bone problems include: Low bone density and osteoporosis, which make your bones weak and more likely to break Osteogenesis imperfecta makes your bones brittle Paget's disease of bone makes them weak Bones can also develop cancer and infections Other bone diseases, which are caused by poor nutrition, genetics, or problems with the rate of bone growth or rebuilding NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary: Bone Disease, also known as bone diseases, is related to brittle bone disorder and osteopetrosis, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Bone Disease is DANCR (Differentiation Antagonizing Non-Protein Coding RNA), and among its related pathways/superpathways are Vitamin D receptor pathway and Endochondral ossification. The drugs Sofosbuvir and Naloxone have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Disease Ontology: 11 A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function.

Wikipedia: 75 Bone disease refers to the medical conditions which affect the... more...

Related Diseases for Bone Disease

Diseases in the Bone Disease family:

Trpv4-Related Bone Disorder

Diseases related to Bone Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 908, show less)
# Related Disease Score Top Affiliating Genes
1 brittle bone disorder 33.2 TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2 PTH
2 osteopetrosis 33.2 TNFSF11 TNFRSF11B TNFRSF11A RUNX2 CTSK CALCA
3 gorham's disease 33.0 TNFSF11 PTH CALCA
4 paget's disease of bone 32.9 TNFSF11 TNFRSF11B TNFRSF11A PTH CTSK CALCA
5 ischemic bone disease 32.8 TNFSF11 SOST RUNX2 PTH DKK1 CTSK
6 paget disease of bone 5, juvenile-onset 32.8 TNFSF11 TNFRSF11B TNFRSF11A CALCA
7 osteitis fibrosa 32.7 SOST PTH FGF23 CALCA BGLAP B2M
8 renal osteodystrophy 32.6 TNFSF11 TNFRSF11B PTH FGF23 CALCA BGLAP
9 chronic kidney disease 32.4 TNFSF11 TNFRSF11B SOST RUNX2 PTH FGF23
10 primary hyperparathyroidism 32.3 TNFSF11 SOST PTH FGF23 CD36 CALCA
11 osteonecrosis 32.3 TNFRSF11B RUNX2 PTH BGLAP ACP5
12 enchondromatosis, multiple, ollier type 32.2 TNFSF11 RUNX2 PTH FGFR3 EXT2 EXT1
13 myeloma, multiple 32.2 TNFSF11 TNFRSF11B TNFRSF11A FGFR3 DKK1 CD36
14 bone resorption disease 32.2 TNFSF11 SOST RUNX2 PTH FGF23 DKK1
15 arthropathy 32.1 TNFSF11 TNFRSF11B TNFRSF11A B2M ALPL
16 hypophosphatasia 32.1 SOST RUNX2 PTH FGF23 BGLAP ALPP
17 hyperparathyroidism 32.1 TNFSF11 TNFRSF11B SOST PTH FGF23 CALCA
18 cleidocranial dysplasia 32.1 TNFSF11 RUNX2 CTSK BGLAP ALPP ALPL
19 craniometaphyseal dysplasia, autosomal dominant 32.1 TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2 BGLAP
20 bone remodeling disease 32.1 TNFSF11 TNFRSF11A SOST RUNX2 PTH FGF23
21 osteomalacia 32.0 TNFSF11 SOST PTH FGF23 CD36 CALCA
22 osteogenesis imperfecta, type iv 32.0 SOST DKK1 CD36
23 bone development disease 32.0 TNFSF11 SOST RUNX2 PTH FGFR3 CTSK
24 rickets 32.0 PTH FGF23 CD36 CALCA BGLAP ALPP
25 kohler's disease 31.9 PTH CALCA
26 cherubism 31.9 TNFSF11 FGFR3 CALCA
27 metachondromatosis 31.9 EXT2 EXT1 CTSK
28 bone structure disease 31.9 RUNX2 PTH BGLAP
29 hypophosphatasia, adult 31.9 PTH ALPL
30 kidney disease 31.8 TNFSF11 TNFRSF11B PTH FGF23 CD36 BGLAP
31 secondary hyperparathyroidism 31.8 TNFRSF11B PTH FGF23 CALCA BGLAP B2M
32 spondyloepiphyseal dysplasia with congenital joint dislocations 31.8 FGFR3 EXT2 EXT1
33 osteoporosis 31.7 TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2 PTH
34 hypophosphatasia, childhood 31.7 SOST ALPL
35 mammary paget's disease 31.7 TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2 PTH
36 hypercalcemia, infantile, 1 31.7 PTH CALCA
37 hypophosphatemia 31.4 SOST PTH FGF23 BGLAP
38 hyperphosphatemia 31.4 TNFRSF11B RUNX2 PTH FGF23 BGLAP
39 hypoparathyroidism 31.4 PTH FGF23 CALCA BGLAP ALPP
40 osteomyelitis 31.3 TNFSF11 TNFRSF11A CTSK CALCA ALPL ACP5
41 endosteal hyperostosis, autosomal dominant 31.3 TNFSF11 TNFRSF11B SOST PTH DKK1 CTSK
42 uremia 31.3 TNFRSF11B RUNX2 PTH FGF23 B2M
43 osteogenic sarcoma 31.2 TNFSF11 TNFRSF11B TNFRSF11A RUNX2 PTH DANCR
44 osteoarthritis 31.1 TNFSF11 TNFRSF11B RUNX2 CTSK BGLAP
45 monoclonal gammopathy of uncertain significance 31.1 TNFSF11 FGFR3 DKK1 B2M
46 parathyroid adenoma 31.1 PTH CALCA ALPP
47 hyperthyroidism 31.1 PTH CALCA BGLAP ACP5
48 beta-thalassemia 31.1 TNFSF11 TNFRSF11B FGF23 BGLAP B2M
49 hypophosphatemic rickets, x-linked dominant 31.0 SOST PTH FGF23 BGLAP ALPL
50 hyperostosis 31.0 TNFRSF11B SOST FGF23 ALPL
51 sclerosteosis 30.9 TNFSF11 SOST RUNX2 PTH DKK1 CTSK
52 glucocorticoid-induced osteoporosis 30.9 TNFSF11 SOST RUNX2 PTH DKK1 CTSK
53 fibrous dysplasia 30.9 TNFSF11 TNFRSF11A FGF23 CALCA BGLAP
54 scoliosis 30.9 TNFSF11 TNFRSF11B TNFRSF11A RUNX2 FGFR3 EXT2
55 sclerosteosis 1 30.9 TNFRSF11B SOST BGLAP
56 osteoporosis, juvenile 30.8 TNFSF11 SOST RUNX2 PTH DKK1 CTSK
57 bone giant cell tumor 30.8 TNFSF11 RUNX2 PTH CTSK CALCA ACP5
58 diabetes mellitus 30.7 TNFSF11 SOST RUNX2 PTH FGF23 CD36
59 mccune-albright syndrome 30.7 SOST PTH FGF23
60 chondrocalcinosis 30.7 TNFRSF11B PTH ALPL
61 pseudohypoparathyroidism 30.7 PTH FGFR3 CALCA BGLAP
62 type 1 diabetes mellitus 30.7 TNFSF11 TNFRSF11B CALCA BGLAP B2M
63 ankylosis 30.7 TNFSF11 TNFRSF11B SOST RUNX2 DKK1 BGLAP
64 fanconi syndrome 30.6 PTH FGF23 B2M
65 familial expansile osteolysis 30.6 TNFSF11 TNFRSF11B TNFRSF11A SOST CTSK ACP5
66 spondyloarthropathy 30.6 TNFSF11 SOST B2M
67 spondyloarthropathy 1 30.6 TNFSF11 TNFRSF11B PTH BGLAP
68 enthesopathy 30.6 SOST PTH FGF23 ALPL
69 osseous heteroplasia, progressive 30.6 RUNX2 PTH BGLAP
70 otosclerosis 30.6 TNFSF11 TNFRSF11B CD36 CALCA
71 spondylitis 30.6 TNFSF11 SOST DKK1
72 osteopetrosis, autosomal dominant 2 30.5 TNFSF11 CTSK BGLAP ACP5
73 connective tissue disease 30.5 TNFSF11 SOST RUNX2 PTH FGFR3 FGF23
74 pycnodysostosis 30.5 TNFSF11 SOST CTSK BGLAP ACP5
75 bursitis 30.5 PTH CALCA ALPL
76 multicentric carpotarsal osteolysis syndrome 30.5 TNFSF11 TNFRSF11B BGLAP B2M
77 osteochondrodysplasia 30.5 TNFSF11 SOST RUNX2 PTH FGFR3 FGF23
78 osteoporosis-pseudoglioma syndrome 30.5 TNFSF11 SOST DKK1
79 exostosis 30.4 SOST RUNX2 EXT2 EXT1 BGLAP
80 osteogenesis imperfecta, type i 30.4 SOST CD36 BGLAP
81 beta-thalassemia major 30.4 PTH BGLAP B2M
82 chondrosarcoma 30.4 RUNX2 FGFR3 EXT2 EXT1
83 parathyroid gland disease 30.4 TNFSF11 SOST PTH FGF23 CALCA BGLAP
84 craniosynostosis 30.3 RUNX2 FGFR3 FGF23 EXT2 BGLAP ALPL
85 camurati-engelmann disease 30.3 TNFRSF11B SOST RUNX2 BGLAP ACP5
86 rheumatoid arthritis 30.3 TNFSF11 TNFRSF11B TNFRSF11A CTSK CD36 BGLAP
87 mineral metabolism disease 30.3 TNFSF11 SOST RUNX2 PTH FGF23 CALCA
88 breast adenocarcinoma 30.3 TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2 PTH
89 periostitis 30.3 TNFRSF11B TNFRSF11A ALPP
90 hereditary multiple osteochondromas 30.3 EXT2 EXT1
91 van buchem disease 30.3 TNFSF11 SOST RUNX2 PTH DKK1 CTSK
92 periodontitis 30.3 TNFSF11 RUNX2 CTSK BGLAP ACP5
93 synovitis 30.3 TNFSF11 TNFRSF11B ACP5
94 metaphyseal dysplasia 30.3 SOST RUNX2 PTH FGF23 ACP5
95 bone osteosarcoma 30.3 TNFSF11 RUNX2 BGLAP
96 diffuse idiopathic skeletal hyperostosis 30.3 SOST PTH DKK1 BGLAP
97 hypervitaminosis d 30.3 PTH FGF23 CALCA
98 reflex sympathetic dystrophy 30.3 CD36 CALCA
99 osteogenesis imperfecta, type vi 30.2 TNFSF11 SOST
100 schimmelpenning-feuerstein-mims syndrome 30.2 PTH FGFR3 FGF23
101 nevus, epidermal 30.2 PTH FGFR3 FGF23
102 osteofibrous dysplasia 30.2 CD36 BGLAP
103 exostoses, multiple, type i 30.2 EXT2 EXT1
104 vitamin d hydroxylation-deficient rickets, type 1a 30.1 PTH FGF23
105 cerebral palsy 30.1 PTH CD36 BGLAP ALPP
106 bone sarcoma 30.0 RUNX2 EXT2 EXT1
107 polycystic bone disease 11.2
108 hypophosphatemic bone disease 11.1
109 inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 1 11.1
110 pierre robin syndrome associated with bone disease 11.1
111 col1a1/2 osteogenesis imperfecta 11.0
112 cystic angiomatosis of bone, diffuse 11.0
113 deafness, x-linked 2 11.0
114 mesomelic dysplasia, kantaputra type 11.0
115 catel-manzke syndrome 11.0
116 rare genetic bone disease 11.0
117 inclusion body myopathy with paget disease of bone and frontotemporal dementia 10.9
118 rare bone disease related to a common gene or pathway defect 10.9
119 bone inflammation disease 10.9
120 diaphanospondylodysostosis 10.9
121 atelosteogenesis, type i 10.9
122 hyperparathyroidism, transient neonatal 10.9
123 osteochondritis dissecans 10.9
124 condensing osteitis of the clavicle 10.9
125 lateral meningocele syndrome 10.9
126 metatropic dysplasia 10.9
127 thanatophoric dysplasia, type i 10.9
128 cortical defects, wormian bones, and dentinogenesis imperfecta 10.9
129 crystal arthropathies 10.9
130 gaucher's disease 10.9
131 gaucher disease, type i 10.9
132 osteonecrosis of the jaw 10.9
133 chronic recurrent multifocal osteomyelitis 10.8
134 paget disease of bone 3 10.8
135 osteogenesis imperfecta, type iii 10.8
136 premature menopause 10.8
137 melorheostosis 10.8
138 exostoses, multiple, type ii 10.8
139 short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans 10.8
140 bent bone dysplasia syndrome 1 10.8
141 hypophosphatasia, infantile 10.8
142 dysbaric osteonecrosis 10.8
143 spinal stenosis 10.8
144 osteochondrosis 10.8
145 hypochondroplasia 10.8
146 kyphomelic dysplasia 10.8
147 geleophysic dysplasia 3 10.8
148 dysostosis multiplex, ain-naz type 10.8
149 hajdu-cheney syndrome 10.7
150 calvarial doughnut lesions with bone fragility 10.7
151 gigantiform cementoma, familial 10.7
152 ischiocoxopodopatellar syndrome with or without pulmonary arterial hypertension 10.7
153 parastremmatic dwarfism 10.7
154 spondyloepimetaphyseal dysplasia, strudwick type 10.7
155 spondylometaphyseal dysplasia, kozlowski type 10.7
156 multiple synostoses syndrome 1 10.7
157 vasculopathy, retinal, with cerebral leukoencephalopathy and systemic manifestations 10.7
158 hypophosphatemic rickets, autosomal dominant 10.7
159 microcephalic osteodysplastic primordial dwarfism, type ii 10.7
160 opsismodysplasia 10.7
161 spondyloepimetaphyseal dysplasia, sponastrime type 10.7
162 spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures 10.7
163 spondylometaepiphyseal dysplasia, short limb-hand type 10.7
164 spondyloepimetaphyseal dysplasia, x-linked 10.7
165 paget disease of bone 2, early-onset 10.7
166 spondyloepimetaphyseal dysplasia, missouri type 10.7
167 spondyloepimetaphyseal dysplasia with joint laxity, type 2 10.7
168 spondyloepimetaphyseal dysplasia, borochowitz-cormier-daire type 10.7
169 multiple synostoses syndrome 2 10.7
170 spondyloepimetaphyseal dysplasia, aggrecan type 10.7
171 multiple synostoses syndrome 3 10.7
172 steel syndrome 10.7
173 multiple synostoses syndrome 4 10.7
174 spondyloepimetaphyseal dysplasia with joint laxity, type 3 10.7
175 spondyloepimetaphyseal dysplasia, isidor-toutain type 10.7
176 cole-carpenter syndrome 10.7
177 spinal disease 10.7
178 sagliker syndrome 10.7
179 idiopathic phalangeal acro-osteolysis 10.7
180 osteochondrosis of the metatarsal bone 10.7
181 mueller-weiss syndrome 10.7
182 ischiovertebral syndrome 10.7
183 klippel-feil syndrome 1, autosomal dominant 10.7
184 epiphyseal dysplasia, multiple, 1 10.7
185 chromosome 8q22.1 duplication syndrome 10.7
186 scheuermann disease 10.7
187 acromesomelic dysplasia 2a 10.7
188 acromesomelic dysplasia 2c 10.7
189 klippel-feil syndrome 2, autosomal recessive 10.7
190 diastrophic dysplasia 10.7
191 acromesomelic dysplasia 2b 10.7
192 atelosteogenesis, type ii 10.7
193 spondyloepiphyseal dysplasia tarda, x-linked 10.7
194 epiphyseal dysplasia, multiple, 2 10.7
195 achondrogenesis, type ib 10.7
196 spondylospinal thoracic dysostosis 10.7
197 acromesomelic dysplasia 1 10.7
198 intervertebral disc disease 10.7
199 acromesomelic dysplasia 3 10.7
200 klippel-feil syndrome 3, autosomal dominant 10.7
201 klippel-feil syndrome 4, autosomal recessive, with nemaline myopathy and facial dysmorphism 10.7
202 spondyloepimetaphyseal dysplasia, faden-alkuraya type 10.7
203 spondyloepimetaphyseal dysplasia, di rocco type 10.7
204 spondyloepimetaphyseal dysplasia, krakow type 10.7
205 acromesomelic dysplasia 4 10.7
206 acromesomelic dysplasia 10.7
207 tooth resorption 10.6 TNFSF11 TNFRSF11A RUNX2 PTH CTSK CALCA
208 benign giant cell tumor 10.6 TNFSF11 TNFRSF11B TNFRSF11A FGF23 CTSK CALCA
209 bone benign neoplasm 10.6 TNFSF11 RUNX2 PTH FGF23 CTSK CALCA
210 giant cell reparative granuloma 10.6 TNFSF11 TNFRSF11A PTH CALCA
211 periapical periodontitis 10.6 TNFSF11 RUNX2 CTSK BGLAP ACP5
212 osteopetrosis, autosomal recessive 2 10.6 TNFSF11 TNFRSF11A CTSK ACP5
213 osteoblastoma 10.6 TNFSF11 PTH FGF23 BGLAP
214 malignant ovarian brenner tumor 10.6 TNFSF11 PTH CALCA
215 hypocalcemia, autosomal dominant 1 10.6 PTH FGF23 CALCA BGLAP
216 phosphorus metabolism disease 10.6 SOST RUNX2 PTH FGF23 BGLAP ALPL
217 teeth hard tissue disease 10.6 TNFSF11 RUNX2 BGLAP ACP5
218 nontoxic goiter 10.6 PTH CALCA BGLAP
219 aortic valve disease 2 10.6 TNFSF11 TNFRSF11B RUNX2 BGLAP
220 dental pulp necrosis 10.6 TNFSF11 RUNX2 BGLAP
221 root resorption 10.6 TNFSF11 TNFRSF11B TNFRSF11A RUNX2 DANCR CALCA
222 tetanic cataract 10.6 PTH CALCA
223 temporomandibular joint anomaly 10.6 TNFSF11 TNFRSF11B
224 arterial calcification of infancy 10.6 RUNX2 FGF23 ALPL
225 primary bone dysplasia 10.6 FGFR3 CTSK ALPL
226 hemiplegia 10.6 CALCA BGLAP ACP5
227 periodontitis, chronic 10.6 TNFSF11 TNFRSF11B
228 substernal goiter 10.6 PTH CALCA
229 crouzon syndrome 10.6 RUNX2 FGFR3 FGF23 BGLAP
230 nerve compression syndrome 10.6 PTH CALCA B2M
231 trichorhinophalangeal syndrome, type ii 10.5 TNFRSF11B EXT2 EXT1
232 isthmus cancer 10.5 PTH CALCA
233 bone mineral density quantitative trait locus 15 10.5
234 malignant giant cell tumor 10.5 TNFSF11 ACP5
235 osteochondroma 10.5 FGFR3 EXT2 EXT1
236 disseminated chorioretinitis 10.5 TNFRSF11B TNFRSF11A
237 chronic apical periodontitis 10.5 TNFSF11 RUNX2
238 femoral cancer 10.5 TNFSF11 ACP5
239 bone mineral density quantitative trait locus 8 10.5
240 microcephaly and chorioretinopathy 1 10.5 FGF23 ALPL
241 ankylosing spondylitis 3 10.5 EXT2 EXT1
242 saethre-chotzen syndrome 10.5 RUNX2 FGFR3 BGLAP
243 brachydactyly 10.5 RUNX2 PTH FGFR3 EXT1
244 telangiectatic osteogenic sarcoma 10.5 TNFSF11 CALCA
245 parietal foramina 10.5 RUNX2 FGFR3 EXT2
246 larsen syndrome 10.5 FGFR3 EXT2 EXT1
247 periosteal osteogenic sarcoma 10.5 EXT2 EXT1
248 uremic neuropathy 10.5 PTH B2M
249 periosteal chondrosarcoma 10.5 EXT2 EXT1
250 hypercementosis 10.5 CTSK ALPL
251 juxtacortical chondroma 10.5 EXT2 EXT1
252 periarthritis 10.5 PTH ALPL
253 charcot-marie-tooth disease, x-linked recessive, 3 10.5 EXT2 EXT1
254 charcot-marie-tooth disease, x-linked recessive, 2 10.5 EXT2 EXT1
255 osteopetrosis, autosomal dominant 1 10.5 TNFRSF11A DKK1
256 hypertelorism, microtia, facial clefting syndrome 10.5 TNFSF11 FGFR3
257 dental abscess 10.5 PTH FGF23
258 chiari malformation 10.5 FGFR3 DKK1
259 endemic goiter 10.5 PTH CALCA
260 vitamin d hydroxylation-deficient rickets, type 1b 10.5 PTH FGF23
261 end stage renal disease 10.4
262 spondylolysis 10.4 PTH CTSK
263 clear cell chondrosarcoma 10.4 RUNX2 EXT2
264 plummer's disease 10.4 PTH CALCA
265 bone mineral density quantitative trait locus 3 10.3
266 liver cirrhosis 10.3
267 cystic fibrosis 10.3
268 nutritional deficiency disease 10.3
269 chronic pyelonephritis 10.3 PTH B2M
270 hypogonadism 10.3
271 prostate cancer 10.3
272 nephrolithiasis, calcium oxalate 10.3
273 primary biliary cholangitis 10.3
274 thalassemia 10.2
275 cholestasis 10.2
276 severe combined immunodeficiency 10.2
277 breast cancer 10.2
278 graves disease 1 10.2
279 renal tubular acidosis 10.2
280 metabolic acidosis 10.2
281 nephrolithiasis 10.2
282 ghosal hematodiaphyseal dysplasia 10.2 TNFSF11 TNFRSF11B
283 deficiency anemia 10.2
284 bone cancer 10.2
285 rare hereditary hemochromatosis 10.2
286 prostate cancer, hereditary, 8 10.1
287 prostate cancer, hereditary, 6 10.1
288 inflammatory bowel disease 10.1
289 overnutrition 10.1
290 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.1
291 celiac disease 1 10.1
292 sickle cell anemia 10.1
293 complement factor b deficiency 10.1
294 nephrocalcinosis 10.1
295 hematologic cancer 10.1
296 myopathy 10.1
297 adenoma 10.1
298 amyloidosis 10.1
299 liver disease 10.1
300 distal renal tubular acidosis 10.1
301 twin-reversed arterial perfusion sequence 10.1
302 vitamin k deficiency bleeding 10.1
303 crohn's disease 10.1
304 sickle cell disease 10.1
305 avascular necrosis 10.1
306 alcohol dependence 10.0
307 hypothyroidism 10.0
308 alcohol use disorder 10.0
309 kidney cancer 10.0
310 lysosomal storage disease 10.0
311 acne 10.0
312 gastrointestinal system disease 10.0
313 fibrosis of extraocular muscles, congenital, 1 10.0
314 hyperparathyroidism 2 with jaw tumors 10.0
315 lung cancer 10.0
316 immune deficiency disease 10.0
317 insulin-like growth factor i 10.0
318 hypophosphatemic rickets, x-linked recessive 10.0
319 leptin deficiency or dysfunction 10.0
320 cystinosis 10.0
321 sarcoma 10.0
322 keratomalacia 10.0
323 cystic echinococcosis 10.0
324 echinococcosis 10.0
325 splenomegaly 10.0
326 idiopathic hypercalciuria 10.0
327 enterocolitis 10.0
328 factor vii deficiency 10.0
329 myelofibrosis 10.0
330 proteasome-associated autoinflammatory syndrome 1 10.0
331 hemophilia a 10.0
332 leptin receptor deficiency 10.0
333 mucopolysaccharidosis-plus syndrome 10.0
334 urolithiasis 10.0
335 combined immunodeficiency 10.0
336 acromegaly 10.0
337 primary hyperoxaluria 10.0
338 cholangitis 10.0
339 autoimmune disease 9.9
340 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 9.9
341 cystinosis, nephropathic 9.9
342 inflammatory bowel disease 1 9.9
343 sjogren syndrome 9.9
344 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 9.9
345 anorexia nervosa 9.9
346 scheie syndrome 9.9
347 nephrotic syndrome 9.9
348 neutropenia 9.9
349 plasmacytoma 9.9
350 perinatal necrotizing enterocolitis 9.9
351 48,xxxy syndrome 9.9
352 48,xxyy syndrome 9.9
353 48,xyyy 9.9
354 49, xxxxy syndrome 9.9
355 49,xxxxx syndrome 9.9
356 bronchopulmonary dysplasia 9.9
357 children's interstitial lung disease 9.9
358 hemophilia 9.9
359 disorder of glyoxylate metabolism 9.9
360 49,xyyyy syndrome 9.9
361 thyroid carcinoma 9.9
362 carpal tunnel syndrome 9.9
363 ehlers-danlos syndrome, arthrochalasia type, 1 9.9
364 leukemia, chronic lymphocytic 9.9
365 hypervitaminosis a 9.9
366 leukemia, acute myeloid 9.9
367 abdominal obesity-metabolic syndrome 1 9.9
368 body mass index quantitative trait locus 1 9.9
369 leukemia, acute lymphoblastic 9.9
370 mononeuropathy of the median nerve, mild 9.9
371 cholangitis, primary sclerosing 9.9
372 short stature, onychodysplasia, facial dysmorphism, and hypotrichosis 9.9
373 fetal alcohol syndrome 9.9
374 alcohol-related birth defects 9.9
375 dialysis-related amyloidosis 9.9
376 sclerosing cholangitis 9.9
377 thrombocytopenia 9.9
378 vascular disease 9.9
379 constipation 9.9
380 pancreatitis 9.9
381 arthritis 9.9
382 ulcerative colitis 9.9
383 47 xxx syndrome 9.9
384 wild type abeta2m amyloidosis 9.9
385 yunis-varon syndrome 9.9
386 coxa vara 9.8
387 factor viii deficiency 9.8
388 fanconi renotubular syndrome 1 9.8
389 legg-calve-perthes disease 9.8
390 systemic lupus erythematosus 9.8
391 myositis 9.8
392 pancreatitis, hereditary 9.8
393 dowling-degos disease 1 9.8
394 down syndrome 9.8
395 persistent hyperplastic primary vitreous, autosomal recessive 9.8
396 hypoascorbemia 9.8
397 body mass index quantitative trait locus 11 9.8
398 norrie disease 9.8
399 body mass index quantitative trait locus 9 9.8
400 body mass index quantitative trait locus 8 9.8
401 body mass index quantitative trait locus 4 9.8
402 body mass index quantitative trait locus 10 9.8
403 body mass index quantitative trait locus 7 9.8
404 body mass index quantitative trait locus 12 9.8
405 body mass index quantitative trait locus 14 9.8
406 myelodysplastic syndrome 9.8
407 body mass index quantitative trait locus 18 9.8
408 body mass index quantitative trait locus 19 9.8
409 body mass index quantitative trait locus 20 9.8
410 waldenstroem's macroglobulinemia 9.8
411 immunoglobulin light chain amyloidosis 9.8
412 osteopoikilosis 9.8
413 obstructive jaundice 9.8
414 biliary atresia 9.8
415 iron metabolism disease 9.8
416 gastric antral vascular ectasia 9.8
417 hemoglobinopathy 9.8
418 acute kidney failure 9.8
419 spinal cord disease 9.8
420 turner syndrome 9.8
421 mastocytosis 9.8
422 dentinogenesis imperfecta 9.8
423 hemolytic anemia 9.8
424 paraplegia 9.8
425 inherited metabolic disorder 9.8
426 lung disease 9.8
427 myeloid leukemia 9.8
428 macroglobulinemia 9.8
429 myotonia 9.8
430 lysosomal disease 9.8
431 scoliosis, isolated 1 9.8
432 fibroma 9.8
433 idiopathic scoliosis 9.8
434 dental caries 9.8
435 spondylosis 9.8
436 chondroma 9.8
437 wilms tumor 1 9.8
438 metaphyseal dysplasia, spahr type 9.8
439 wilms tumor 5 9.8
440 multiple epiphyseal dysplasia 9.8
441 collecting duct carcinoma 9.8
442 pseudohypoparathyroidism, type ia 9.7
443 carcinoid tumors, intestinal 9.7
444 fibrodysplasia ossificans progressiva 9.7
445 renal cell carcinoma, nonpapillary 9.7
446 neurofibromatosis, type i 9.7
447 oculodentodigital dysplasia 9.7
448 scleroderma, familial progressive 9.7
449 vitiligo-associated multiple autoimmune disease susceptibility 6 9.7
450 alkaptonuria 9.7
451 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.7
452 schwartz-jampel syndrome, type 1 9.7
453 myxedema 9.7
454 neuraminidase deficiency 9.7
455 phenylketonuria 9.7
456 rhabdomyosarcoma 2 9.7
457 ataxia with vitamin e deficiency 9.7
458 wilson disease 9.7
459 prostatic hyperplasia, benign 9.7
460 suppression of tumorigenicity 12 9.7
461 hyperhomocysteinemia 9.7
462 vitiligo-associated multiple autoimmune disease susceptibility 1 9.7
463 pulmonary disease, chronic obstructive 9.7
464 hepatitis c virus 9.7
465 osteogenesis imperfecta, type v 9.7
466 ewing sarcoma 9.7
467 lung cancer susceptibility 3 9.7
468 congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 9.7
469 gastric cancer 9.7
470 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.7
471 tatton-brown-rahman syndrome 9.7
472 urinary tract infection 9.7
473 vitamin d-dependent rickets 9.7
474 sensorineural hearing loss 9.7
475 short bowel syndrome 9.7
476 microcytic anemia 9.7
477 heart disease 9.7
478 conn's syndrome 9.7
479 alveolar echinococcosis 9.7
480 cartilage disease 9.7
481 acute leukemia 9.7
482 diarrhea 9.7
483 exocrine pancreatic insufficiency 9.7
484 sapho syndrome 9.7
485 alcoholic liver cirrhosis 9.7
486 hepatitis c 9.7
487 viral hepatitis 9.7
488 hepatitis 9.7
489 hemangioma 9.7
490 dermatitis 9.7
491 adenocarcinoma 9.7
492 skin carcinoma 9.7
493 cellulitis 9.7
494 syphilis 9.7
495 systemic scleroderma 9.7
496 hyperglycemia 9.7
497 neuromuscular disease 9.7
498 hypokalemia 9.7
499 calciphylaxis 9.7
500 plasma cell neoplasm 9.7
501 juvenile rheumatoid arthritis 9.7
502 peptic ulcer disease 9.7
503 measles 9.7
504 neurofibromatosis 9.7
505 homocystinuria 9.7
506 viral infectious disease 9.7
507 plasma cell leukemia 9.7
508 pik3ca-related overgrowth spectrum 9.7
509 aminoaciduria 9.7
510 cytokine deficiency 9.7
511 growth hormone deficiency 9.7
512 oto-palatal-digital syndrome 9.7
513 primary bone cancer 9.7
514 spondylarthropathy 9.7
515 bunion 9.7
516 chronic pain 9.7
517 encephalopathy 9.7
518 mucopolysaccharidoses 9.7
519 disorder of mineral absorption and transport 9.7
520 epiphysiolysis of the hip 9.7
521 pik3ca-related overgrowth syndrome 9.7
522 overgrowth syndrome 9.7
523 keratitis, hereditary 9.7
524 sella turcica, bridged 9.7
525 sprengel deformity 9.7
526 neuropathy, hereditary sensory and autonomic, type iii 9.7
527 rhizomelic limb shortening with dysmorphic features 9.7
528 klippel-feil syndrome 9.7
529 blount's disease 9.7
530 fgfr craniosynostosis syndromes 9.7
531 syncope 9.7
532 campomelic dysplasia and related disorders 9.7
533 leri-weill dyschondrosteosis 9.6
534 marfan syndrome 9.6
535 metaphyseal chondrodysplasia, jansen type 9.6
536 neural tube defects 9.6
537 vater/vacterl association 9.6
538 beta-aminoisobutyric aciduria 9.6
539 tumoral calcinosis, hyperphosphatemic, familial, 1 9.6
540 chondrodysplasia, blomstrand type 9.6
541 lysinuric protein intolerance 9.6
542 thrombocytopenia-absent radius syndrome 9.6
543 menkes disease 9.6
544 muscular dystrophy, duchenne type 9.6
545 diabetes and deafness, maternally inherited 9.6
546 cinca syndrome 9.6
547 myocardial infarction 9.6
548 avascular necrosis of femoral head, primary, 1 9.6
549 human immunodeficiency virus type 1 9.6
550 majeed syndrome 9.6
551 osteomyelitis, sterile multifocal, with periostitis and pustulosis 9.6
552 osteogenesis imperfecta, type x 9.6
553 graft-versus-host disease 9.6
554 x-linked chondrodysplasia punctata 2 9.6
555 secondary hypertrophic osteoarthropathy 9.6
556 microphthalmia 9.6
557 meningocele 9.6
558 lipoid nephrosis 9.6
559 male infertility 9.6
560 brain cancer 9.6
561 algoneurodystrophy 9.6
562 rheumatic fever 9.6
563 ossifying fibroma 9.6
564 calcinosis 9.6
565 hepatitis b 9.6
566 central nervous system origin vertigo 9.6
567 complex regional pain syndrome 9.6
568 lung squamous cell carcinoma 9.6
569 pituitary-dependent cushing's disease 9.6
570 thyroid gland medullary carcinoma 9.6
571 radiculopathy 9.6
572 osgood-schlatter's disease 9.6
573 acute myocardial infarction 9.6
574 muscular dystrophy 9.6
575 multiple epiphyseal dysplasia, autosomal dominant 9.6
576 plod1-related kyphoscoliotic ehlers-danlos syndrome 9.6
577 trichorhinophalangeal syndrome 9.6
578 chronic graft versus host disease 9.6
579 systemic autoimmune disease 9.6
580 chondromyxoid fibroma 9.6
581 complications after hematopoietic stem cell transplantation 9.6
582 monostotic fibrous dysplasia 9.6
583 lethal chondrodysplasia 9.6
584 fgfr3-related chondrodysplasia 9.6
585 precursor t-cell acute lymphoblastic leukemia 9.6
586 cone-rod dystrophy 2 9.6
587 corneal dystrophy, epithelial basement membrane 9.6
588 polycystic liver disease 1 with or without kidney cysts 9.6
589 pseudoachondroplasia 9.6
590 progressive pseudorheumatoid dysplasia 9.6
591 hypophosphatemic rickets, autosomal recessive, 1 9.6
592 histiocytosis-lymphadenopathy plus syndrome 9.6
593 epiphyseal dysplasia, multiple, 5 9.6
594 carney complex variant 9.6
595 porphyria, acute hepatic 9.6
596 complement component 3 deficiency, autosomal recessive 9.6
597 autosomal recessive hypophosphatemic rickets 9.6
598 primary pigmented nodular adrenocortical disease 9.6
599 epithelial basement membrane dystrophy 9.6
600 autonomic neuropathy 9.6
601 pulmonary tuberculosis 9.6
602 rhabdomyosarcoma 9.6
603 teratocarcinoma 9.6
604 teratoma 9.6
605 lymphatic system disease 9.6
606 complement component 3 deficiency 9.6
607 myeloid sarcoma 9.6
608 diabetic neuropathy 9.6
609 type ii collagen disorders 9.6
610 lathyrism 9.6
611 paresthesia 9.6
612 autosomal recessive malignant osteopetrosis 9.6
613 hypocalcemic vitamin d-dependent rickets 9.6
614 achondroplasia 9.6
615 adult syndrome 9.6
616 apnea, obstructive sleep 9.6
617 atherosclerosis susceptibility 9.6
618 gastroesophageal reflux 9.6
619 caffey disease 9.6
620 hepatocellular carcinoma 9.6
621 human coronavirus sensitivity 9.6
622 maturity-onset diabetes of the young, type 1 9.6
623 elliptocytosis 2 9.6
624 multiple endocrine neoplasia, type i 9.6
625 esophageal cancer 9.6
626 exudative vitreoretinopathy 1 9.6
627 glioma susceptibility 1 9.6
628 hypercholesterolemia, familial, 1 9.6
629 mastocytosis, cutaneous 9.6
630 thyroid carcinoma, familial medullary 9.6
631 metaphyseal chondrodysplasia, schmid type 9.6
632 gnathodiaphyseal dysplasia 9.6
633 osteomesopyknosis 9.6
634 ovalocytosis, southeast asian 9.6
635 prolidase deficiency 9.6
636 periodontitis, aggressive, 1 9.6
637 pernicious anemia 9.6
638 pheochromocytoma 9.6
639 polycystic kidney disease 1 with or without polycystic liver disease 9.6
640 hutchinson-gilford progeria syndrome 9.6
641 psoriasis 1 9.6
642 pulmonary hypertension, primary, 1 9.6
643 retinal detachment 9.6
644 sarcoidosis 1 9.6
645 small cell cancer of the lung 9.6
646 temporal arteritis 9.6
647 tobacco addiction 9.6
648 tuberous sclerosis 1 9.6
649 arachnoid cysts, intracranial 9.6
650 right atrial isomerism 9.6
651 biliary atresia, extrahepatic 9.6
652 cholestasis, progressive familial intrahepatic, 1 9.6
653 charge syndrome 9.6
654 conotruncal heart malformations 9.6
655 baller-gerold syndrome 9.6
656 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1 9.6
657 leukoencephalopathy, hereditary diffuse, with spheroids 1 9.6
658 trichohepatoenteric syndrome 1 9.6
659 glutaric acidemia i 9.6
660 hemochromatosis, type 1 9.6
661 lymphoma, hodgkin, classic 9.6
662 homocystinuria due to cystathionine beta-synthase deficiency 9.6
663 hypogonadism, male 9.6
664 chylomicron retention disease 9.6
665 marden-walker syndrome 9.6
666 mucopolysaccharidosis, type vii 9.6
667 ceroid lipofuscinosis, neuronal, 5 9.6
668 3-methylglutaconic aciduria, type iii 9.6
669 osteopetrosis, autosomal recessive 1 9.6
670 hyperoxaluria, primary, type i 9.6
671 subacute sclerosing panencephalitis 9.6
672 pseudoxanthoma elasticum 9.6
673 pyle disease 9.6
674 rothmund-thomson syndrome, type 2 9.6
675 testicular germ cell tumor 9.6
676 hypothyroidism, congenital, nongoitrous, 1 9.6
677 vitamin d-dependent rickets, type 2a 9.6
678 dent disease 1 9.6
679 agammaglobulinemia, x-linked 9.6
680 bone mineral density quantitative trait locus 18 9.6
681 focal dermal hypoplasia 9.6
682 paine syndrome 9.6
683 rett syndrome 9.6
684 aging 9.6
685 gallbladder disease 1 9.6
686 neurofibromatosis-noonan syndrome 9.6
687 stuve-wiedemann syndrome 1 9.6
688 systemic lupus erythematosus 1 9.6
689 ossification of the posterior longitudinal ligament of spine 9.6
690 psoriasis 2 9.6
691 microvascular complications of diabetes 1 9.6
692 langerhans cell histiocytosis 9.6
693 lymphoma, non-hodgkin, familial 9.6
694 psoriasis 7 9.6
695 aneurysmal bone cysts 9.6
696 nasopharyngeal carcinoma 9.6
697 creatinine clearance quantitative trait locus 9.6
698 meningioma, familial 9.6
699 resting heart rate, variation in 9.6
700 patent ductus arteriosus 1 9.6
701 psoriatic arthritis 9.6
702 anxiety 9.6
703 parathyroid carcinoma 9.6
704 major depressive disorder 9.6
705 choanal atresia, posterior 9.6
706 aplastic anemia 9.6
707 hyperparathyroidism 3 9.6
708 osteogenesis imperfecta, type vii 9.6
709 malaria 9.6
710 elliptocytosis 1 9.6
711 inflammatory bowel disease 19 9.6
712 sarcoidosis 2 9.6
713 psoriasis 11 9.6
714 microvascular complications of diabetes 2 9.6
715 microvascular complications of diabetes 3 9.6
716 microvascular complications of diabetes 4 9.6
717 microvascular complications of diabetes 5 9.6
718 microvascular complications of diabetes 6 9.6
719 microvascular complications of diabetes 7 9.6
720 premature ovarian failure 7 9.6
721 tuberous sclerosis 2 9.6
722 odontoid hypoplasia 9.6
723 psoriasis 13 9.6
724 psoriasis 14, pustular 9.6
725 intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 9.6
726 leukemia, acute lymphoblastic 3 9.6
727 nevus comedonicus 9.6
728 helix syndrome 9.6
729 elliptocytosis 3 9.6
730 gastric adenocarcinoma and proximal polyposis of the stomach 9.6
731 angina pectoris 9.6
732 pulmonary hypertension 9.6
733 congenital hypothyroidism 9.6
734 adult t-cell leukemia/lymphoma 9.6
735 exudative vitreoretinopathy 9.6
736 female breast cancer 9.6
737 diffuse large b-cell lymphoma 9.6
738 lymphoplasmacytic lymphoma 9.6
739 paraganglioma 9.6
740 peripheral artery disease 9.6
741 sleep apnea 9.6
742 oral squamous cell carcinoma 9.6
743 lymphoma 9.6
744 brain glioma 9.6
745 colitis 9.6
746 crohn's colitis 9.6
747 basal ganglia calcification 9.6
748 persistent hyperplastic primary vitreous 9.6
749 cardiac arrest 9.6
750 inguinal hernia 9.6
751 atypical chronic myeloid leukemia, bcr-abl1 negative 9.6
752 progressive familial intrahepatic cholestasis 9.6
753 fibrogenesis imperfecta ossium 9.6
754 intestinal pseudo-obstruction 9.6
755 childhood acute lymphocytic leukemia 9.6
756 non-alcoholic fatty liver disease 9.6
757 polycystic kidney disease 9.6
758 non-alcoholic steatohepatitis 9.6
759 b-lymphoblastic leukemia/lymphoma 9.6
760 human cytomegalovirus infection 9.6
761 mild cognitive impairment 9.6
762 rapidly involuting congenital hemangioma 9.6
763 central diabetes insipidus 9.6
764 dermatomyositis 9.6
765 chronic meningitis 9.6
766 common cold 9.6
767 pre-eclampsia 9.6
768 hydrocephalus 9.6
769 cholesteatoma of middle ear 9.6
770 gestational diabetes 9.6
771 iron deficiency anemia 9.6
772 leukocoria 9.6
773 visual epilepsy 9.6
774 head and neck cancer 9.6
775 cryptococcosis 9.6
776 peripheral retinal degeneration 9.6
777 spinal muscular atrophy 9.6
778 nephrogenic diabetes insipidus 9.6
779 leukemia 9.6
780 pancytopenia 9.6
781 bell's palsy 9.6
782 hepatitis a 9.6
783 enterocele 9.6
784 quadriplegia 9.6
785 cardiovascular system disease 9.6
786 plasmodium vivax malaria 9.6
787 focal segmental glomerulosclerosis 9.6
788 uveitis 9.6
789 gout 9.6
790 ehlers-danlos syndrome 9.6
791 reading disorder 9.6
792 hepatic encephalopathy 9.6
793 tuberous sclerosis 9.6
794 eclampsia 9.6
795 hypermobility syndrome 9.6
796 facial paralysis 9.6
797 plasmodium falciparum malaria 9.6
798 childhood type dermatomyositis 9.6
799 ochronosis 9.6
800 urticaria 9.6
801 neuroendocrine tumor 9.6
802 richter's syndrome 9.6
803 epilepsy 9.6
804 intrahepatic cholestasis 9.6
805 impotence 9.6
806 optic nerve disease 9.6
807 malignant fibrous histiocytoma 9.6
808 dysostosis 9.6
809 arteriosclerosis 9.6
810 colonic benign neoplasm 9.6
811 hereditary elliptocytosis 9.6
812 sensory peripheral neuropathy 9.6
813 agammaglobulinemia 9.6
814 rectosigmoid junction neoplasm 9.6
815 rectosigmoid cancer 9.6
816 hairy cell leukemia 9.6
817 glomerulonephritis 9.6
818 multiple endocrine neoplasia 9.6
819 lipid metabolism disorder 9.6
820 lipomatosis 9.6
821 fibrosarcoma 9.6
822 histiocytosis 9.6
823 breast disease 9.6
824 systemic mastocytosis 9.6
825 skin disease 9.6
826 extramedullary plasmacytoma 9.6
827 solitary osseous plasmacytoma 9.6
828 nail disease 9.6
829 secondary syphilis 9.6
830 erdheim-chester disease 9.6
831 pustulosis of palm and sole 9.6
832 seminoma 9.6
833 middle ear disease 9.6
834 intestinal disease 9.6
835 t-cell acute lymphoblastic leukemia 9.6
836 peripheral nervous system disease 9.6
837 bladder urachal carcinoma 9.6
838 fibromyalgia 9.6
839 acquired immunodeficiency syndrome 9.6
840 myositis ossificans 9.6
841 cerebrovascular disease 9.6
842 compartment syndrome 9.6
843 b-cell lymphoma 9.6
844 muscular atrophy 9.6
845 neuroblastoma 9.6
846 tertiary syphilis 9.6
847 cataract 9.6
848 ileus 9.6
849 retinal degeneration 9.6
850 dermatitis herpetiformis 9.6
851 monocytic leukemia 9.6
852 eating disorder 9.6
853 neuropathy 9.6
854 acute megakaryocytic leukemia 9.6
855 lupus erythematosus 9.6
856 rosacea 9.6
857 psoriasis 9.6
858 autosomal dominant polycystic kidney disease 9.6
859 parapsoriasis 9.6
860 diabetes insipidus 9.6
861 fatty liver disease 9.6
862 pulmonary embolism 9.6
863 smoldering myeloma 9.6
864 neurofibroma 9.6
865 tenosynovitis 9.6
866 irritable bowel syndrome 9.6
867 congenital syphilis 9.6
868 hereditary distal renal tubular acidosis 9.6
869 hereditary paraganglioma-pheochromocytoma syndromes 9.6
870 hypermobile ehlers-danlos syndrome 9.6
871 acute myeloid leukemia with recurrent genetic anomaly 9.6
872 bone marrow necrosis 9.6
873 carcinoid syndrome 9.6
874 catastrophic antiphospholipid syndrome 9.6
875 chromosomal triplication 9.6
876 cryopyrin-associated periodic syndrome 9.6
877 glioma 9.6
878 homocysteinemia 9.6
879 human t-cell leukemia virus type 1 9.6
880 leukemia, t-cell, chronic 9.6
881 lymphangiomatosis 9.6
882 medullary sponge kidney 9.6
883 mitochondrial dna-associated leigh syndrome 9.6
884 oncogenic osteomalacia 9.6
885 pediatric autoimmune neuropsychiatric disorders associated with streptococcus in 9.6
886 precocious puberty 9.6
887 primary agammaglobulinemia 9.6
888 pure autonomic failure 9.6
889 single ventricular heart 9.6
890 soft tissue sarcoma 9.6
891 age-related hearing loss 9.6
892 juvenile primary osteoporosis 9.6
893 dysautonomia 9.6
894 hypotonia 9.6
895 posttransplant acute limbic encephalitis 9.6
896 glial tumor 9.6
897 diffuse lymphatic malformation 9.6
898 germ cell tumor 9.6
899 fetal anticonvulsant syndrome 9.6
900 idiopathic nephrotic syndrome 9.6
901 phalangeal microgeodic syndrome 9.6
902 disorders of vitamin d metabolism 9.6
903 familial intrahepatic cholestasis 9.6
904 anterior cutaneous nerve entrapment syndrome 9.6
905 solitary bone cyst 9.6
906 primary bone dysplasia with increased bone density 9.6
907 refractory anemia 9.6
908 vitreoretinopathy 9.6

Graphical network of the top 20 diseases related to Bone Disease:



Diseases related to Bone Disease

Symptoms & Phenotypes for Bone Disease

UMLS symptoms related to Bone Disease:


back pain; muscle cramp; sciatica; bone pain

MGI Mouse Phenotypes related to Bone Disease:

45 (showing 14, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 ALPL B2M BGLAP CALCA CD36 CTSK
2 growth/size/body region MP:0005378 10.36 ALPL B2M CD36 CTSK DKK1 EXT1
3 limbs/digits/tail MP:0005371 10.35 ACP5 ALPL CTSK DKK1 EXT1 FGF23
4 cellular MP:0005384 10.25 ALPL B2M BGLAP CD36 CTSK DKK1
5 immune system MP:0005387 10.22 ACP5 ALPL B2M BGLAP CD36 CTSK
6 endocrine/exocrine gland MP:0005379 10.19 ALPL B2M BGLAP CD36 CTSK FGF23
7 skeleton MP:0005390 10.19 ACP5 ALPL BGLAP CALCA CD36 CTSK
8 craniofacial MP:0005382 10.16 ALPL CTSK DKK1 EXT1 FGFR3 PTH
9 digestive/alimentary MP:0005381 10.13 ALPL B2M CD36 CTSK EXT1 FGF23
10 respiratory system MP:0005388 10.02 ALPL CALCA CTSK DKK1 FGF23 FGFR3
11 reproductive system MP:0005389 10.02 ALPL B2M BGLAP CTSK FGF23 FGFR3
12 hematopoietic system MP:0005397 9.97 ACP5 ALPL B2M BGLAP CD36 CTSK
13 mortality/aging MP:0010768 9.8 ALPL B2M CALCA CD36 DKK1 EXT1
14 integument MP:0010771 9.28 B2M CALCA CD36 FGF23 FGFR3 RUNX2

Drugs & Therapeutics for Bone Disease

Drugs for Bone Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 270, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
2
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
3
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
4
Cobicistat Approved Phase 4 1004316-88-4 24950485 25151504
5
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
6
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 77335690 67683363
7
Elvitegravir Approved Phase 4 697761-98-1 23083982 5277135
8
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
9
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
10
Ethinylestradiol Approved Phase 4 57-63-6 5991
11
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
12
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
13
Phylloquinone Approved, Investigational Phase 4 572-96-3, 84-80-0 5280585 5284607
14 Strontium ranelate Approved, Withdrawn Phase 4 135459-87-9
15
Lactulose Approved Phase 4 4618-18-2 11333
16
Tibolone Approved, Investigational Phase 4 5630-53-5 5470 444008
17
Gliclazide Approved Phase 4 21187-98-4 3475
18
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
19
Norelgestromin Approved, Investigational Phase 4 53016-31-2 13752005 9568628
20
Raloxifene Approved, Investigational Phase 4 82640-04-8, 84449-90-1 5035
21
Sodium fluoride Approved Phase 4 7681-49-4
22
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
23
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715
24
Desogestrel Approved Phase 4 54024-22-5 40973
25
Dapagliflozin Approved Phase 4 461432-26-8 9887712
26
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
27
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
28
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
29
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
30
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
31
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
32
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
33
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3, 63283-36-3 5283731
34
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
35 Menaquinone Investigational Phase 4 1182-68-9
36
Tenofovir Experimental, Investigational Phase 4 147127-20-6, 202138-50-9 464205 6398764
37 Analgesics, Opioid Phase 4
38 Sofosbuvir-velpatasvir drug combination Phase 4
39 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
40 Emtricitabine tenofovir alafenamide Phase 4
41 Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
42 Calcium, Dietary Phase 4
43 Expectorants Phase 4
44 Citrate Phase 4
45 Respiratory System Agents Phase 4
46 Ergocalciferols Phase 4
47 Hepcidins Phase 4
48
Vitamin D2 Phase 4 3249
49 Olive Phase 4
50 Liver Extracts Phase 4
51 Mitogens Phase 4
52 Contraceptives, Oral, Combined Phase 4
53 Contraceptives, Oral Phase 4
54 Contraceptive Agents Phase 4
55 Aromatase Inhibitors Phase 4
56 Hemostatics Phase 4
57
Naphthoquinone Phase 4
58 Antifibrinolytic Agents Phase 4
59 Vitamin K Phase 4
60 Coagulants Phase 4
61
Insulin Phase 4
62 Insulin, Globin Zinc Phase 4
63 Cyclosporins Phase 4
64 Antihypertensive Agents Phase 4
65 Vitamin K 2 Phase 4
66 Androgen Antagonists Phase 4
67 Dipeptidyl-Peptidase IV Inhibitors Phase 4
68 Ortho Evra Phase 4
69 Protective Agents Phase 4
70 Hydroxycholecalciferols Phase 4
71 Estrogen Receptor Modulators Phase 4
72 Estrogen Receptor Antagonists Phase 4
73 Estrogen Antagonists Phase 4
74 Selective Estrogen Receptor Modulators Phase 4
75 Fluorides Phase 4
76 Listerine Phase 4
77 Anti-Infective Agents, Local Phase 4
78 NuvaRing Phase 4
79 Sodium-Glucose Transporter 2 Inhibitors Phase 4
80 Hypoglycemic Agents Phase 4
81 Dialysis Solutions Phase 4
82 Anti-Infective Agents Phase 4
83 Cytochrome P-450 Enzyme Inhibitors Phase 4
84 Cytochrome P-450 CYP3A Inhibitors Phase 4
85 Anti-HIV Agents Phase 4
86 Antiviral Agents Phase 4
87 Anti-Retroviral Agents Phase 4
88 HIV Integrase Inhibitors Phase 4
89 Reverse Transcriptase Inhibitors Phase 4
90 Integrase Inhibitors Phase 4
91 Vasoconstrictor Agents Phase 4
92 Atazanavir Sulfate Phase 4
93
protease inhibitors Phase 4
94 HIV Protease Inhibitors Phase 4
95 Raltegravir Potassium Phase 4
96
Calcium Nutraceutical Phase 4 7440-70-2 271
97
Zinc cation Approved, Experimental, Investigational Phase 3 7440-66-6, 23713-49-7 32051
98
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
99
Medroxyprogesterone acetate Approved, Investigational Phase 3 520-85-4, 71-58-9 10631 6279
100
Lamivudine Approved, Investigational Phase 3 134678-17-4 60825
101
Dolutegravir Approved Phase 3 1051375-16-6 57414794 54726191
102
Etidronic acid Approved Phase 3 2809-21-4, 7414-83-7 3305
103
Hesperidin Approved, Investigational Phase 3 520-26-3 53477767
104
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
105
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
106
Risedronic acid Approved, Investigational Phase 3 105462-24-6 5245
107
Ibandronate Approved, Investigational Phase 3 114084-78-5 60852
108
Tetracycline Approved, Vet_approved Phase 2, Phase 3 60-54-8 5353990
109
Genistein Investigational Phase 2, Phase 3 446-72-0 5280961
110
Resveratrol Investigational Phase 3 501-36-0 445154
111
Black cohosh Experimental Phase 3
112 Androgens Phase 3
113 Antioxidants Phase 3
114 Contraceptive Agents, Male Phase 3
115 Estrogens, Conjugated (USP) Phase 3
116 Soy Bean Phase 3
117 Protein Kinase Inhibitors Phase 2, Phase 3
118 Analgesics Phase 3
119 Platelet Aggregation Inhibitors Phase 3
120 Acidophilus Phase 3
121 Calcium Supplement Phase 3
122 Vitamin K 1 Phase 3
123 Factor VIII Phase 3
124 calcium channel blockers Phase 3
125 Anti-Bacterial Agents Phase 2, Phase 3
126 Phytoestrogens Phase 3
127 Progestins Phase 3
128
D-Leucine Experimental, Investigational, Nutraceutical Phase 3 328-38-1, 61-90-5 439524 6106
129
Silicon Approved, Investigational Phase 1, Phase 2 7440-21-3 4082203
130
Teriparatide Approved, Investigational Phase 2 52232-67-4 16133850 155817470
131
Calcium carbonate Approved, Investigational Phase 2 471-34-1
132
Mecasermin Approved, Investigational Phase 2 68562-41-4
133
Sorbitol Approved, Investigational Phase 2 69-65-8, 50-70-4 453 6251 5780
134
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 155817456
135
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
136
Epitestosterone Approved, Experimental, Investigational Phase 2 481-30-1, 58-22-0 5408 10204 6013
137
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0 21873174 65157
138
Testosterone enanthate Approved Phase 2 315-37-7 9416
139
Methyltestosterone Approved Phase 2 58-18-4 6010
140
Inulin Approved, Investigational, Nutraceutical Phase 1, Phase 2 9005-80-5 24763
141
Saracatinib Investigational Phase 2 379231-04-6 10302451
142
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2 91976570
143 Sulfalene Phase 1, Phase 2
144 Potassium phosphate Phase 2
145 Gastrointestinal Agents Phase 2
146 Anti-Ulcer Agents Phase 2
147 Antacids Phase 2
148 Dihydroxycholecalciferols Phase 2
149
Oleuropein Phase 2 32619-42-4 5281544
150
Calcitonin Phase 2
151 Katacalcin Phase 2 16172926
152 Antibodies Phase 2
153 Immunoglobulins Phase 2
154 Bifidobacterium Phase 1, Phase 2
155 Antibodies, Monoclonal Phase 2
156 Chicory Phase 1, Phase 2
157 Prolactin Release-Inhibiting Factors Phase 2
158 Anabolic Agents Phase 2
159 Antineoplastic Agents, Hormonal Phase 2
160 Testosterone 17 beta-cypionate Phase 2
161
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
162
Radium Ra 223 dichloride Approved, Investigational Phase 1 444811-40-9
163
Abaloparatide Approved, Investigational Phase 1 247062-33-5
164
Cytarabine Approved, Experimental, Investigational Phase 1 147-94-4, 65-46-3 596 6253 6175
165
Etanercept Approved, Investigational Phase 1 185243-69-0
166
Melatonin Approved, Nutraceutical, Vet_approved Phase 1 73-31-4 896
167
Equol Investigational Phase 1 531-95-3 91469
168 glucocorticoids Phase 1
169 Tubulin Modulators Phase 1
170 Antimitotic Agents Phase 1
171 Albumin-Bound Paclitaxel Phase 1
172 Antirheumatic Agents Phase 1
173 Anti-Inflammatory Agents, Non-Steroidal Phase 1
174 Analgesics, Non-Narcotic Phase 1
175 Anti-Inflammatory Agents Phase 1
176
Furosemide Approved, Vet_approved 54-31-9 3440
177
Hydrochlorothiazide Approved, Vet_approved 58-93-5 3639
178
Chlorhexidine Approved, Vet_approved 55-56-1 2713 9552079
179
Clindamycin Approved, Vet_approved 18323-44-9, 24729-96-2 29029
180
Rifampicin Approved 13292-46-1 135512673 5381226 135900090
181 Hops Approved
182
Methylthioninium Approved, Experimental, Investigational 61-73-4, 7060-82-4 6099
183
Pancrelipase Approved, Investigational 53608-75-6 8519
184
Caffeine Approved 58-08-2 2519
185
Ivacaftor Approved 873054-44-5 16220172
186
Interferon beta-1b Approved 145155-23-3
187
Interferon beta-1a Approved, Investigational 145258-61-3
188
Tetracosactide Approved Early Phase 1 16960-16-0 16133802 16129617
189
Carbamazepine Approved, Investigational 298-46-4 2554
190
Valproic acid Approved, Investigational 99-66-1 3121
191
Topiramate Approved 97240-79-4 5284627
192
Hydrocortisone Approved, Vet_approved 50-23-7 3640 5754
193
Hydrocortisone succinate Approved 2203-97-6 3643
194
Hydrocortisone acetate Approved, Vet_approved 50-03-3
195
Moxonidine Approved, Investigational 75438-57-2 4810
196
Perindopril Approved 82834-16-0, 107133-36-8 107807
197
Bisoprolol Approved 66722-44-9 2405
198
Losartan Approved 114798-26-4 3961
199
Fosfomycin Approved 23155-02-4 446987
200
Racepinephrine Approved, Vet_approved 51-43-4, 329-65-7 838 5816
201
Cimetidine Approved, Investigational 51481-61-9 2756
202
Infliximab Approved 170277-31-3
203
Ethanol Approved 64-17-5 702
204
Salicylic acid Approved, Investigational, Vet_approved 69-72-7 338
205
Basiliximab Approved, Investigational 179045-86-4
206
Lithium carbonate Approved 554-13-2
207
Zoledronic acid Approved 118072-93-8 68740
208
Creatine Approved, Investigational, Nutraceutical 57-00-1 586
209
Prasterone Approved, Investigational, Nutraceutical 53-43-0 5881
210
Uric acid Investigational 69-93-2 1175
211
Formononetin Investigational 485-72-3 5280378
212
Daidzein Experimental 486-66-8 5281708
213
Biochanin A Investigational 491-80-5 5280373
214
Menatetrenone Investigational 56973-41-2, 863-61-6 5282367
215 Chrysarobin
216 Astragalus
217 Sodium Potassium Chloride Symporter Inhibitors
218 Sodium Chloride Symporter Inhibitors
219 Chlorhexidine gluconate
220 Red Clover
221
Clindamycin phosphate 32603
222 Clindamycin palmitate
223 Antibiotics, Antitubercular
224
Levan Early Phase 1 9013-95-0 22833608
225 Magnesium Supplement
226 Zinc Supplement
227 Pancreatin
228 Tea
229 Horseradish Tree
230 Glatiramer Acetate
231 interferons
232 Interferon-beta
233 Adjuvants, Immunologic
234 (T,G)-A-L
235
beta-Endorphin Early Phase 1
236 Melanocyte-Stimulating Hormones Early Phase 1
237 Endothelial Growth Factors Early Phase 1
238 Endorphins Early Phase 1
239 Adrenocorticotropic Hormone Early Phase 1
240 Neurotransmitter Agents Early Phase 1
241 Sodium Channel Blockers
242 Anticonvulsants
243 Psychotropic Drugs
244 Diuretics, Potassium Sparing
245 Omega 3 Fatty Acid
246 Taxane 108169
247 Hydrocortisone 17-butyrate 21-propionate
248 Whey Protein
249
Terephthalic acid 100-21-0 7489
250 Chelating Agents
251 Caseins
252 Adrenergic beta-1 Receptor Antagonists
253 Adrenergic Antagonists
254 Adrenergic Agents
255 Sympatholytics
256 Adrenergic beta-Antagonists
257 Epinephryl borate
258 Polymethyl Methacrylate
259 Dermatologic Agents
260 Anesthetics
261 DHEA (Dehydroepiandrosterone)
262
abobotulinumtoxinA
263 Botulinum Toxins, Type A
264 Botulinum Toxins
265 Calcineurin Inhibitors
266 Antilymphocyte Serum
267 Pharmaceutical Solutions
268 Diphosphonates
269 Proton Pump Inhibitors
270
Ginseng Investigational, Nutraceutical 50647-08-0

Interventional clinical trials:

(showing 524, show less)
# Name Status NCT ID Phase Drugs
1 Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study Unknown status NCT03549312 Phase 4 Genvoya;Epclusa;Biktarvy
2 The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, Fatigue and Inflammatory Activity in Patients With Crohn's Disease: a Randomized Controlled Trial Unknown status NCT02704624 Phase 4
3 Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients Completed NCT02999204 Phase 4 Vitamin D3
4 Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients (CHAMBER): A Multicenter, Double-blind, Randomized, Placebo-controlled Trial Completed NCT02214563 Phase 4
5 Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Disodium Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant Completed NCT00657852 Phase 4 Disodium pamidronate;Placebo
6 A Multicentre, Double-Blind, Randomized Placebo-Controlled Study of 70mg Alendronate Once Weekly for the Prevention and Treatment of Osteoporosis in Canadian Adult Cystic Fibrosis Patients Completed NCT00157690 Phase 4 Alendronate;Placebo
7 Denosumab Counteracts Metabolic Bone Disease in Chronic Intestinal Failure Patients: A Randomized, Controlled Clinical Trial Completed NCT02853539 Phase 4 Denosumab
8 A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia Completed NCT00357331 Phase 4 potassium citrate
9 Regenerative Potential of a Collagen Membrane Associated or Not to Bovine Bone in Class II Furcation Defects - A Randomized Clinical Trial. Completed NCT04450849 Phase 4
10 Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Completed NCT00772395 Phase 4 Risedronate;Placebo
11 An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
12 A 6 Months, Open-Label Phase IV Study to Confirm the Safety and Efficacy of Single Intravenous Dose of 5 mg Zoledronic Acid for the Patients of Paget's Disease of Bone (PDB) in China Completed NCT00774020 Phase 4 Zoledronic acid
13 A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH > 150pg/ml) on a Ciclosporin A and Glucocorticoid Based Immunosuppressive Regimen. Completed NCT00738257 Phase 4 Pamidronate
14 NMR Imaging and Stereological Analysis of Trabecular Bone in Female Subjects 60 and Older at Risk of Fracture Receiving Either Zoledronic Acid or Teriparatide Completed NCT01153425 Phase 4 Teriparatide;Zoledronic Acid
15 An Open Label, Reclast®/Aclasta®, Re-treatment of Relapsed Patients With Paget's Disease of Bone Who Participated in the CZOL446K2304 and CZOL446K2305 Core Registration Studies Completed NCT00740129 Phase 4 Zoledronic Acid
16 A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients Completed NCT01215890 Phase 4 risedronate;placebo
17 Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium- and Bone Metabolism After Successful Surgery? - Part I Completed NCT01222026 Phase 4 Strontium Ranelate + Ca/Vitamin-D;Placebo
18 Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients: A Prospective, Randomized Placebo-controlled Double Blind Trial Completed NCT02976246 Phase 4
19 An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate Completed NCT02598453 Phase 4 Ibandronate
20 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Completed NCT00504166 Phase 4 alendronate sodium
21 High Dosage Vitamin D in the Treatment of Osteoporosis in Postmenopausal Women Completed NCT00491920 Phase 4 cholecalciferol (Vitamin D3);placebo
22 Bisphosphonate Therapy for Osteogenesis Imperfecta Completed NCT00159419 Phase 4 Alendronate;Pamidronate
23 Does Treatment of Hypovitaminosis D Increase Calcium Absorption? Completed NCT00581828 Phase 4 Vitamin D
24 A Multi-center, Randomized, Double-blind, Double-dummy Study in Postmenopausal Women With Low Bone Mineral Density to Compare the Effects of a Single Dose of i.v. Zoledronic Acid 5 mg, With Daily Oral Raloxifene 60 mg OD on Bone Turnover Markers Completed NCT00431444 Phase 4 Raloxifene;Zoledronic acid;Placebo oral pills;Placebo intravenous (i.v.) infusion
25 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
26 A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant System Over 24 Months, for Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol Completed NCT01960361 Phase 4
27 Double-blind, Placebo-controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of Oral Ibandronate Once Monthly in Postmenopausal Women With Osteopenia Completed NCT00129623 Phase 4 Placebo;ibandronate [Bonviva/Boniva]
28 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
29 The P.O.W.E.R. STUDY (Premenopause, Osteopenia/Osteoporosis, Women, Alendronate, Depression) Completed NCT00006180 Phase 4 Alendronate
30 Post US Approval Voluntary Registry Study to Determine Incidence of Hypocalcemia Post Reclast® Treatment in Patients With Paget's Disease After Institution of Educational Strategies to Improve Adherence to Calcium and Vitamin D Supplementation Completed NCT00668200 Phase 4 Reclast (ZOL446, zoledronic acid)
31 Comparison Between Pamidronate and Zoledronic Acid for the Treatment of Heart and Lung Transplant Related Osteopaenia and Osteoporosis Completed NCT00164008 Phase 4 zoledronic acid vs pamidronate
32 A Randomized, Double-Blind, Multicenter, Parallel Pilot Clinical Trial to Study the Efficay of a Treatment of Lactulose + Vitamin D + Calcium 0.5 g Concurrently Controlled With a Standard Treatment (Vit D + Calcium) in Bone Mass Preservation Among Postmenopausal Women Completed NCT00160264 Phase 4 Lactulose, Vitamin D, Calcium
33 A Multinational, Randomized, Double-Blind, Parallel Group Comparative Trial on the Effects of 2 Years Treatment With Tibolone (1.25 mg Org OD 14) and Raloxifene (60 mg) on Bone Mineral Density in Osteopenic Postmenopausal Women Completed NCT00431431 Phase 4 tibolone;raloxifen
34 Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid Completed NCT00172029 Phase 4 Zoledronic acid
35 Influence of Alfacalcidol on Falls in Elderly Postmenopausal, Alendronate-Treated, Osteopenic/Osteoporotic Women With High Risk of Falls Completed NCT00168909 Phase 4 alfacalcidol;placebo
36 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density Completed NCT00939874 Phase 4 Raltegravir
37 Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? Completed NCT00766532 Phase 4 Aromatase Inhibitor
38 A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate Completed NCT02604836 Phase 4 Ibandronate
39 Efficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term Glucocorticoids Completed NCT01287533 Phase 4 Ibandronate;Placebo
40 Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability.A Comparison Between Vildagliptin and Gliclazide MR Completed NCT01679899 Phase 4 Vildagliptin;Gliclazide MR
41 Primary Mechanisms Underlying the Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis and Bone Metabolism in Young Women Completed NCT02367833 Phase 4 Combined Oral Contraceptive;Transdermal Contraceptive;Contraceptive Vaginal Ring
42 An Open, Prospective, Multi-center Study to Evaluate Bone Loss, the Survival Rate of SPI Implant System and Implant Stability Over a 24 Months, in Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol. Completed NCT02367261 Phase 4
43 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
44 A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease. Completed NCT00365131 Phase 4 Cerezyme (imiglucerase for injection)
45 Vitamin D Status and Bone Metabolism Status in Children With Congenital Epidermolysis Bullosa Recruiting NCT05141838 Phase 4 Vitamin D
46 Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia: an 1-year Randomized Controlled Trial Recruiting NCT05386784 Phase 4 Raloxifene plus cholecalciferol;Cholecalciferol
47 Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery Recruiting NCT04087096 Phase 4 Denosumab;Placebo;Zoledronic Acid
48 A Randomized, Double-blind Study of the Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum Vitamin D Levels in Pediatric Patients With Cystic Fibrosis Recruiting NCT05276960 Phase 4 Cholecalciferol Pill
49 Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Patients With Chronic Kidney Disease Recruiting NCT04522622 Phase 4 Teriparatide
50 The Effect of Oral vs. Non-oral Contraceptive Therapy on Bone Turnover Using 41Ca Methodology Active, not recruiting NCT02367846 Phase 4 Combined Oral Contraceptive (COC);Contraceptive Vaginal Ring (CVR)
51 Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial Active, not recruiting NCT02286830 Phase 4 Zoledronic acid
52 The Effect of Effervescent and Buffered Alendronate on Bone Turnover Compared to Conventional Alendronate: A Randomized Non-inferiority Study Active, not recruiting NCT05325515 Phase 4 Conventional alendronate;Effervescent and buffered alendronate
53 Lanthanum Carbonate Versus Calcium Carbonate for Vascular Abnormalities in Patients With Chronic Kidney Disease and Hyperphosphatemia Enrolling by invitation NCT02237534 Phase 4 Lanthanum carbonate;Calcium Carbonate
54 A Multicenter Randomized Exploratory Clinical Trial to Evaluate the Effect of Bone Metabolism and the Efficacy of Evogliptin and Dapagliflozin for Blood Sugar in the Menopause Female Patients With Osteopenia and Type 2 Diabetes Not yet recruiting NCT04706637 Phase 4 Evogliptin;Dapagliflozin
55 Denosumab for the Prevention of Fragility Fractures in Hemodialysis: a Pilot Study for an Innovative, Randomized-controlled Trial, Embedded in Routine Care Not yet recruiting NCT05096195 Phase 4 Denosumab 60 mg/ml [Prolia]
56 Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density Not yet recruiting NCT04597931 Phase 4 Romosozumab;Zoledronic Acid
57 Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo Suspended NCT01734824 Phase 4 Denosumab;Teriparatide;Placebo Denosumab;Placebo Teriparatide
58 A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
59 Switching HIV-positive Women on Tenofovir/Emtricitabine Plus Boosted Atazanavir to RALtegravir Plus Boosted ATazanavir: A Pilot Randomized Clinical Trial Investigating 48-weeks Changes in Bone Mineral Density Terminated NCT01902186 Phase 4 raltegravir and atazanavir and ritonavir;tenofovir/emtricitabine and atazanavir and ritonavir
60 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus. Withdrawn NCT02011620 Phase 4
61 An Open-Label, Multicentre Trial to Evaluate the Time Associated With the Preparation and Administration of Denosumab and Pamidronate in Subjects With Solid Tumors and Metastatic Bone Disease in Canada Withdrawn NCT02101164 Phase 4 pamidronate
62 Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome Withdrawn NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
63 Pilot Study Evaluating the Effects of Estradiol for Hypogonadal Women With Cystic Fibrosis and Osteopenia Withdrawn NCT03724955 Phase 4 Estradiol 2 mg
64 Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS Unknown status NCT02809781 Phase 2, Phase 3 Etanercept
65 Impact of Biliopancreatic Limb Length of 60cm vs 100cm in Roux-en-Y Gastric Bypass on Bone Mineral Density 2 Years After Surgery Unknown status NCT04377230 Phase 3
66 Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women Unknown status NCT02186600 Phase 3 Calcium Carbonate;Vitamin D3;Risedronate
67 Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis Unknown status NCT00209469 Phase 2, Phase 3 alendronate sodium
68 Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial Unknown status NCT04034199 Phase 3 Denosumab;Zoledronic Acid
69 Improving Low Bone Mass With Vibration Therapy for Girls With Adolescent Idiopathic Scoliosis (AIS) - A Randomized Controlled Trial Completed NCT01108211 Phase 3
70 Postmenopausal Estrogen/Progestin Interventions (PEPI) Completed NCT00000466 Phase 3 estrogens, conjugated;medroxyprogesterone;progesterone;estrogen replacement therapy
71 Women's Health Initiative (WHI) Completed NCT00000611 Phase 3 hormone replacement therapy;estrogens;progestins;estrogen replacement therapy;calcium;vitamin D
72 Relationship Between Drug Exposure and DNA Markers With Depot Medroxyprogesterone Acetate-associated Side Effects in Adolescents Completed NCT01461824 Phase 3 Depot medroxyprogesterone acetate (DMPA)
73 Randomized, Double-blinded, Placebo Controlled Study to Assess Efficacy of Oral 35 mg Per Week Risedronate in Preventing Bone Loss in Postmenopausal Women With Aromatase Inhibitor Therapy for Breast Cancer. Completed NCT00859703 Phase 3 Risedronate;Placebo
74 Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies Completed NCT02561039 Phase 3 Ibandronate
75 Effects of Resveratrol on Inflammation in Type 2 Diabetic Patients. A Double-blind Randomized Controlled Trial Completed NCT02244879 Phase 3
76 A Randomized Controlled Trial of Zoledronate in the Treatment of Osteopenia in Children and Adolescents With Crohn's Disease Completed NCT00798473 Phase 3 zoledronic acid
77 Functional Yogurt Powder Effect on Bone Health Biomarkers Completed NCT02629341 Phase 3
78 A 6-Month, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Alendronate 280-mg Oral Buffered Solution Once Weekly in Patients With Paget's Disease of Bone Completed NCT00480662 Phase 3 alendronate
79 A Multicenter, Double-Blind, Double-Dummy, Randomized, Active- Controlled, 3-Year Study to Evaluate the Antiresorptive Efficacy, Safety and Tolerability of a Ultra-Low Dose Estradiol Transdermal Delivery System Releasing 0.014 mg / Day Versus Oral Raloxifene Hydrochloride 60 mg / Day - as a Therapy for the Prevention of Osteoporosis in Postmenopausal Female Osteopenic Patients. Completed NCT00310531 Phase 3 Menostar (Estradiol, BAY86-5435);Raloxifene
80 Evaluation of the Clinical Use of Vitamin K Supplementation in Post-Menopausal Women With Osteopenia (ECKO Trial) Completed NCT00150969 Phase 3
81 A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy Completed NCT00925600 Phase 3
82 An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density Completed NCT00325468 Phase 3 AMG 162
83 Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis Completed NCT00277251 Phase 2, Phase 3 Alendronate
84 Randomized, Double-Blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observation Period Completed NCT00103740 Phase 3 zoledronic acid;placebo to zoledronic acid;Risedronate;Placebo to risedronate;Calcium and vitamin D supplements
85 Bone Sparing Effects of Soy Phytoestrogens in Menopause Completed NCT00076050 Phase 3
86 Randomized, Double-blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observational Period Completed NCT00051636 Phase 3 Zoledronic Acid;Risedronate;Placebo to Risedronate;Placebo to Zoledronic Acid
87 A HR-pQCT Study in Postmenopausal Women Previously Treated With Denosumab Completed NCT00890981 Phase 3 Placebo
88 Vascular and Skeletal Protective Effects of Genistein in Postmenopausal Women Completed NCT00355953 Phase 2, Phase 3 Genistein
89 Effects of Hesperidin on Bone Mineral Density and Bone Metabolism of Postmenopausal Women Completed NCT00330096 Phase 3 Hesperidin
90 A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia Completed NCT00132808 Phase 3 Zoledronic Acid;Placebo
91 Prevention of Postmenopausal Bone Loss With Nitric Oxide Completed NCT00043719 Phase 3 Nitroglycerin ointment;Calcium supplement with vitamin D
92 Randomized, Open Label Study to Evaluate Renal Safety of Intravenous Bondronat 6 mg Infusions Over 15 Minutes Versus 60 Minutes in Patients With Metastatic Bone Disease Due to Breast Cancer Completed NCT02716792 Phase 3 Ibandronate
93 A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Compare the Efficacy and Safety of Denosumab Versus Placebo in Males With Low Bone Mineral Density Completed NCT00980174 Phase 3 60 mg denosumab
94 A Randomized, Double-blind Study of the Effect of Oral Monthly Bonviva on in Vivo Bone Micro-architecture Parameters in Post-menopausal Women With Osteopenia Completed NCT00545207 Phase 3 ibandronate [Bonviva/Boniva];Placebo
95 Prevention of Postmenopausal Bone Loss in Osteopenic Women With Alendronate Given on a 70 mg Once-every Two Week Regimen: a 2-year, Double-blind, Placebo-controlled Clinical Trial. Completed NCT00463268 Phase 3 alendronate;placebo
96 An Open-Label, Randomized, MultiCenter Study to Evaluate the Use of Zolendronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Positive and/or Progesterone Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy Completed NCT00171340 Phase 3 Zoledronic acid;Letrozole
97 Evaluation of the Efficacy and Tolerability of Alendronate Versus Denosumab in Kidney Transplant Patients With Reduced Bone Mineral Density Completed NCT04169698 Phase 2, Phase 3 Denosumab 60 mg/ml [Prolia];Alendronate 70Mg Tab
98 MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM PROTEASE INHIBITORS TO DOLUTEGRAVIR IN HIV-1-INFECTED SUBJECTS WITH LOW BONE MINERAL DENSITY Completed NCT01966822 Phase 3 Dolutegravir, 50mg every 24 hours;Protease Inhibitor/ritonavir
99 A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Denisty Completed NCT00330460 Phase 3 Alendronate;Denosumab
100 Effect of Combined Exercise Therapy and Isoflavone Supplementation on Prevention of Osteoporosis Completed NCT00204425 Phase 3
101 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma Completed NCT01345019 Phase 3 Denosumab;Zoledronic acid;Placebo to Denosumab;Placebo to zoledronic acid;Denosumab (for the open-label treatment phase)
102 Effects of Whole-Body Electromyostimulation on Osteoporosis and Sarcopenia in Independently Living, Frail Elderly Females Completed NCT01296776 Phase 3
103 An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis Completed NCT00523341 Phase 3
104 A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density Completed NCT00515463 Phase 3
105 The Effect of Daily Whole-Body Vibration on Tibial Trabecular Bone Mineral Density in Osteopenic Postmenopausal Women Completed NCT00420940 Phase 3
106 A Non-Invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D-Peripheral Quantitative Computed Tomography (3D-pQCT) Completed NCT00386360 Phase 3 Placebo comparator;risedronate
107 To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women Completed NCT00145275 Phase 3 zoledronic acid
108 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer Completed NCT00089661 Phase 3 Placebo;AMG 162 / Denosumab
109 PTH Once Weekly Research (POWR) Completed NCT00065637 Phase 3 Teriparatide;Placebo teriparatide
110 Valuating the Effects of Oligopin Supplementation on the Turnover of Bone Formation and Antioxidant Changes in Postmenopausal Osteopenic Women: A Randomized Double-blind Clinical Trial With Placebo-concurrent Controls Completed NCT03260803 Phase 3 Oligopin;Placebo
111 Effects of Soy Isoflavone on Bone Health Among Saudi Female Students Imam Abdulrahman Bin Faisal University. Completed NCT04547010 Phase 3
112 Severe Decrease of Growth Velocity in Children With Anorexia Nervosa. Therapeutic Trial of Growth Hormone Completed NCT01626833 Phase 2, Phase 3 SOMATROPINE* : Norditropine® simplexx®
113 Prospective Biomarkers of Bone Metabolism in Hemophilia A Completed NCT02306694 Phase 3 Advate
114 A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease Completed NCT00685646 Phase 3 antiandrogen therapy;zoledronic acid
115 The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH) Completed NCT00417612 Phase 3 Paricalcitol
116 Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study Recruiting NCT04779216 Phase 3 Romosozumab Prefilled Syringe;Placebo;Alendronate 70Mg Tab
117 1-2 PUNCH: Palliative UNConventional Hypofractionation Trial for Metastatic Bone Disease Recruiting NCT05115331 Phase 3
118 Models of Primary Osteoporosis Screening in Male Veterans Recruiting NCT04079868 Phase 2, Phase 3
119 Bone Graft Cultivation by Periosteal Elevation Recruiting NCT05270317 Phase 3
120 The Effect of Teriparatide on the Early Postoperative Hypocalcemia After Parathyroidectomy in Dialysis Patients: a Pilot, Randomized Trial Enrolling by invitation NCT04750460 Phase 3 Teriparatide
121 Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery Not yet recruiting NCT04922333 Phase 3 Risedronate;Placebo
122 Effect of Exercise and Exercise + Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause Terminated NCT00663104 Phase 3
123 A Randomized, Placebo-controlled, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain Terminated NCT00099203 Phase 3 ibandronate [Bondronat];zoledronic acid
124 Clinical Trial of Continuous Low-Dose Hormone Replacement Therapy Combined With Alendronate in Postmenopausal Women With Low Bone Density Terminated NCT00000430 Phase 3 Alendronate;Estrogen/progestin therapy
125 Bone Disease in Severely Burned Children Terminated NCT00591162 Phase 2, Phase 3 Tetracycline
126 A Randomized, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain Terminated NCT00099177 Phase 3 ibandronate [Bondronat];zoledronic acid
127 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a 91-Day Extended-Cycle Combination Oral Contraceptive (Seasonale) for the Treatment of Low Bone Mineral Density in Adolescent Females With Secondary Amenorrhea and Osteopenia Withdrawn NCT00117260 Phase 3 Seasonale (levonorgestrel and ethinyl estradiol)
128 Early Effect of Vitamin D in Primary Hyperparathyroidism Withdrawn NCT01329666 Phase 2, Phase 3
129 The Efficacy of the Probiotic Supplement Vivomixx on Prevention of Bone Loss in Early Menopausal Women With Breast Cancer Treated With an Aromatase Inhibitor Unknown status NCT03518268 Phase 1, Phase 2 Vivomixx;Placebo
130 Tai Chi for Osteopenic Women: A Pilot Randomized Controlled Trial Unknown status NCT01039012 Phase 2
131 Bisphosphonate Therapy for HIV-Associated Osteopenia Unknown status NCT00102908 Phase 2 Zoledronate;Zoledronate placebo
132 A Parallel Group Study to Evaluate the Effect of Six Weeks of Treatment With Nasal Spray (NS) ZT-034, Compared to Subcutaneous (SC) Forteo and Placebo, on Bone Formation, as Assessed by Stimulation of Serum P1NP Levels in Postmenopausal Women With Low Bone Mass Unknown status NCT01604057 Phase 2 ZT-034 Low Dose Nasal Spray;ZT-034 Mid Dose Nasal Spray;ZT-034 High Dose Nasal Spray;Teriparatide;Placebo
133 Oral Potassium Acid Phosphate Supplementation for Preterm Neonates; a Comparison of Oral Thin Films and Standard Oral Therapy. Unknown status NCT01676844 Phase 2 Oral thin film therapy (Potassium acid phosphate oral thin films);Standard therapy (Potassium acid phosphate oral solution)
134 Feasibility and Dosing Study of Bone Density Changes With and Without PEMF Following Immobilization of the Forearm Completed NCT00067834 Phase 1, Phase 2
135 CVD Risk and Health in Postmenopausal Phytoestrogen Users Completed NCT00000613 Phase 2 genistein
136 Comparison Between Low and High Doses of Prophylactic Vitamin D in Prevention of Osteopenia of Prematurity Completed NCT04768439 Phase 2 Low Dose Vitamin D;High Dose Vitamin D
137 Effects of Recombinant Human Insulin Like Growth Factor-1 (rhIGF-1) on Bone Metabolism in Adolescent Girls With Anorexia Nervosa Completed NCT00720122 Phase 2 Recombinant human insulin like growth factor-1 (rhIGF-1)
138 A Single-arm, Open-label, Multicenter, Dose Titration Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects With Chronic Kidney Disease-Mineral and Bone Disorder Completed NCT01414114 Phase 2 Etelcalcetide
139 Long-Term Effects of Giving Nursing-Home Residents Bread Fortified With 125 Micrograms (5000 IU) Vitamin D3 Per Daily Serving Completed NCT00789503 Phase 1, Phase 2
140 Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation Completed NCT02074631 Phase 2 Pamidronate;Calcium and vitamin D
141 Vitamin D Supplementation and Bone Health in Adults With Diabetic Nephropathy Completed NCT01476501 Phase 2 Vitamin D3
142 Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV) Completed NCT01228318 Phase 2 Zoledronic acid
143 Phase 2 Study of Patients Undergoing Bariatric Surgery (Laparoscopic Gastric Bypass) and Evaluation of Bone Metabolism With/Without Vitamin D/Calcium Supplementation Completed NCT01739855 Phase 2 Calciferol, calcium carbonate
144 A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density Completed NCT01406548 Phase 2 BPS804 20mg/Kg;Placebo to 20mg/Kg BPS804
145 A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease. Completed NCT00558272 Phase 2 AZD0530;Zoledronic Acid
146 A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density Completed NCT00293813 Phase 2 Alendronate;Denosumab;Placebo
147 Metabolic Acidosis and Its Impact on Mineral Metabolism and Physical Performance in Renal Transplant Patients Completed NCT00913796 Phase 2 Potassium citrate;Potassium chloride
148 Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer Completed NCT00181584 Phase 2 Zoledronic acid
149 A Randomized, Double-Blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women With Low Bone Mineral Density Completed NCT00043186 Phase 2 Placebo;Denosumab;Alendronate
150 Bone Response to Soy Isoflavones in Women Completed NCT00043745 Phase 2
151 Clinical and Radiographic Evaluation of Crestal Bone Loss Around Implant With or Without Platform Switching Design (Randomized Clinical Trial, Split Mouth Design) Completed NCT02761226 Phase 2
152 Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis. Completed NCT00170911 Phase 2 AAE581
153 Bone Sparing by Calcium Salts With and Without Extra Phosphorus Completed NCT00074711 Phase 2 Calcium carbonate;Calcium Phosphate
154 Optimization of Calcium Absorption and Bone Formation During Early Puberty Completed NCT00022867 Phase 1, Phase 2 Nondigestible oligosaccharide (NDO)
155 A Multi-centre, Randomized, Double Blind, Parallel Group Study to Investigate Efficacy and Safety of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis Completed NCT00532337 Phase 2 ONO-5334
156 Effect of Supraphysiological rhGH on Bone Metabolism in Patients With Anorexia Nervosa Completed NCT00283595 Phase 2 Recombinant Human Growth Hormone;Placebo for Recombinant Human Growth Hormone
157 A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab Completed NCT00887965 Phase 2 Previous denosumab
158 A Randomised, Double Blind, Parallel Group, 12-month Comparison of a Standardized Olive Extract With Placebo in Postmenopausal Women With Decreased Bone Mineral Density Completed NCT00789425 Phase 2
159 A Phase 2 Randomized Study of LY2541546 Versus Placebo in Postmenopausal Women With Low Bone Mineral Density: An Evaluation of the Dose Response Relationship Using Bone Mineral Density Completed NCT01144377 Phase 2 LY2541546;Placebo
160 A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Safety and Efficacy of Oral Recombinant Salmon Calcitonin (rsCT) in the Prevention of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture Completed NCT01292187 Phase 2 Oral calcitonin at dinnertime;Oral placebo at dinnertime;Oral calcitonin at bedtime;Oral placebo at bedtime
161 The Effect of Exercise in Postmenopausal Women With Low Bone Density Completed NCT00643331 Phase 2
162 Short-term Effects of Hesperidin on Bone Biomarkers in Postmenopausal Women: a Randomized Placebo-controlled Trial Completed NCT00545116 Phase 2
163 A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women With Breast Cancer and Established Bone Metastases (MBD) Completed NCT00399802 Phase 2 ZA;Odanacatib;Odanacatib matching placebo;ZA matching placebo
164 a Six Month, Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group Study to Estimate the Pharmacodynamic Response of Two Risedronate Regimens Compared With 5mg Daily : 150mg Monthly Dose for Six Months and 15mg Daily for Thirty Days Followed by 150mg Monthly Dose for 5 Months in Postmenopausal Women With Low Bone Density. Completed NCT00351091 Phase 2 RISEDRONATE
165 Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease Completed NCT00004488 Phase 2 alendronate sodium;calcium carbonate;cholecalciferol
166 A Randomised, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density Completed NCT00896532 Phase 2 Placebo to Romosozumab;Alendronate;Teriparatide;Romosozumab;Denosumab;Placebo to Denosumab;Zoledronic acid
167 To Test the Effect of Calcifediol Hy.D Supplementation on Muscle Function and Bone Quality in Younger Postmenopausal Women With Osteopenia: a Double-blind Randomized Placebo-controlled Trial Completed NCT02527668 Phase 2
168 A Phase I/II Study of 166Ho-DOTMP With Peripheral Blood Progenitor Cell Support for Refractory or Recurrent Ewing's Sarcoma Family of Tumors With Bone Disease Completed NCT00006234 Phase 1, Phase 2
169 A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE on Myeloma Related Bone Disease Completed NCT01286077 Phase 2 bortezomib
170 The Effect of Semaglutide (Ozempic) on Bone Turnover in Patients With Increased Fracture Risk: a Randomized Placebo-controlled Clinical Trial Recruiting NCT04702516 Phase 1, Phase 2 Ozempic;Placebo
171 Effects of Romosozumab on Bone Health in Women With Spinal Cord Injury and Osteoporosis Recruiting NCT04708886 Phase 2 Romosozumab;Alendronate
172 The Effect of Etelcalcetide on Bone-tissue Properties and Calcification Propensity in End Stage Kidney Disease Recruiting NCT03960437 Phase 2 Etelcalcetide
173 OsteoPreP: The Effect of Probiotic Supplementation on Bone, Muscle, and Glucose Metabolism in Postmenopausal Women: A Randomised Placebo-controlled Trial Recruiting NCT05348694 Phase 1, Phase 2
174 Bone Response After Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospective, Phase II, Randomized, Multicenter Study Recruiting NCT03336983 Phase 2 Zoledronic Acid;Enzalutamide
175 A Phase 2 Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia Recruiting NCT05419050 Phase 2 denosumab
176 An Open Label Pilot Study of Denosumab Treatment for Fibrous Dysplasia Active, not recruiting NCT03571191 Phase 2 Denosumab
177 A Phase II Multicenter, Single Arm, Open-Label Trial to Evaluate the Efficacy and Safety of Denosumab in Treatment of Post-Allogenic Hematopoietic Stem Cell Transplant Bone Loss Active, not recruiting NCT03925532 Phase 2
178 Phase II Protocol Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone Active, not recruiting NCT02880319 Phase 2 Stereotactic Body Radiation Therapy (SBRT)
179 A Phase I/II Randomized, Double-blind, Controlled Study to Evaluate Efficacy and Safety of Vitamin D on Bone Mineral Density and Markers of Bone Resorption in Aromatase Inhibitor-induced Bone Loss in Women With Breast Cancer. Terminated NCT00904423 Phase 1, Phase 2 Vitamin D
180 Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss Terminated NCT00844480 Phase 2 zoledronic acid;placebo
181 Testosterone and Alendronate in Hypogonadal Men Terminated NCT01460654 Phase 2 Testosterone;Alendronate;Placebo Alendronate;Placebo Testosterone
182 The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass Terminated NCT01928082 Phase 2 Transdermal estradiol
183 Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab Terminated NCT03457818 Phase 2 Denosumab 60 mg/ml [Prolia]
184 Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) Withdrawn NCT03549689 Phase 2 Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC);Current tenofovir alafenamide (TAF)-containing ART regimen
185 A Phase 2, 24-Week, Multicenter, Randomized, Parallel-Group, Dose-Ranging Study To Evaluate The Effect Of Teriparatide Nasal Spray On Bone Mineral Density In Postmenopausal Women With Low Bone Mineral Density Withdrawn NCT00624481 Phase 2 Teriparatide;Teriparatide Nasal Spray
186 Phase 1 Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women Unknown status NCT01397838 Phase 1 Pro-Bone
187 A Phase 1, Open-Label Pharmacokinetic Study to Investigate Drug Penetration in the Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery Completed NCT02726438 Phase 1 Debio 1450
188 A Phase I Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of RN564 In Women With Osteopenia And In Healthy Men Completed NCT01293487 Phase 1
189 A Study to Evaluate Food Effect on Pharmacokinetics Parameters After Administration of ONO-5920/YM529 Intermittent Formulation Completed NCT00965978 Phase 1 ONO-5920 / YM529
190 An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate Safety and Tolerability of Radium Ra 223 Dichloride (BAY88-8223) Administered in Combination With Paclitaxel in Cancer Subjects With Bone Lesions Completed NCT02442063 Phase 1 Radium Ra 223 dichloride (Xofigo, BAY88-8223);paclitaxel
191 Bone Morphogenetic Protein-2 Increase as Substitute for Autologous Bone Graft After Ilizarow Treatment for Arthritis and Degenerative Bones. Completed NCT01690260 Phase 1 Bone Morphogenetic Protein 2
192 Assessing the Efficacy of Melatonin on Bone Health in Peri-menopausal Women Completed NCT01152580 Phase 1
193 The Effect of Chymosin on the Intestinal Absorption of Calcium: A Randomized Controlled Cross-over Trial Completed NCT01370941 Phase 1
194 Dose Finding Pilot Study of Cabozantinib (XL184) Administered Orally as Monotherapy for the Treatment of Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With Bone Disease Completed NCT01582295 Phase 1 Cabozantinib
195 A Phase I, Randomized, Multicenter, Double-Blind Study of MK0429 in the Treatment of Men With Hormone Refractory Prostate Cancer and Metastatic Bone Disease Completed NCT00302471 Phase 1 Comparator: MK0429
196 A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density Completed NCT01101048 Phase 1 Placebo;AMG 167
197 A Randomized, Double-blind, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women Completed NCT01059435 Phase 1 Romosozumab;Placebo
198 Study to Determine the Pharmacokinetics of a Single 14C-labeled Intravenous Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose to Postmenopausal Women With Osteopenia or Osteoporosis Completed NCT00577850 Phase 1 risedronate;alendronate
199 A Randomized, Double-blind, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 167 in Healthy Men and Postmenopausal Women Completed NCT00902356 Phase 1 AMG 167;Placebo
200 A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Postmenopausal Japanese Women Completed NCT01101061 Phase 1 Romosozumab;Placebo
201 Metabolism and Bone Health Completed NCT00244907 Phase 1
202 A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Effect of AMG 785 on Parameters of Bone Quality of the Forearm Using pQCT in Postmenopausal Women With Low Bone Mineral Density Completed NCT00950950 Phase 1 Romosozumab;Placebo
203 A Phase Ib/II Multicenter Dose-determination Study, With an Adaptive, Randomized, Placebo-controlled, Double-blind Phase II, Using Various Repeated IV Doses of BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients With Prior Skeletal-related Event Completed NCT00741377 Phase 1 BHQ880;Zoledronic acid
204 Phase 1 Study of Combination Strontium, Melatonin and Nutritional Co-factors on Bone Health and Quality of Life in Postmenopausal Women With Osteopenia Completed NCT01870115 Phase 1
205 A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women With Low Bone Mass Completed NCT01825785 Phase 1 Romosozumab;Placebo
206 A Prospective, Single Arm Study to Evaluate the PK, PD and Usability of Abaloparatide-sMTS in Postmenopausal Women With Low Bone Mineral Density Completed NCT04366726 Phase 1
207 A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of the Safety and Tolerability of Intravenous LLP2A-Alendronate in Adult Men and Women With Osteopenia Secondary to Glucocorticoids Completed NCT03197623 Phase 1 LLP2A-ALENDRONATE;Placebo
208 Magnesium Supplementation in Elderly Females Completed NCT02549521 Phase 1
209 A Phase 1 Multicenter, Open-label, Dose-escalation Trial of MBC-11, an Etidronate-ara-C Conjugate in Patients With Malignant Tumors With Cancer-induced Bone Disease (CIBD) Completed NCT02673060 Phase 1 MBC-11
210 Effect of a Ghrelin Receptor Agonist on Muscle and Bone Active, not recruiting NCT04021706 Phase 1 Anamorelin Hydrochloride;Placebo
211 The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis Terminated NCT01294397 Phase 1 Etanercept;Denosumab
212 A Randomized, Double-Blind, Placebo-Controlled, Repeated-Dose Study to Assess the Safety, Tolerability, and Preliminary Effects of CHI-554 in Postmenopausal Women With Osteopenia Terminated NCT05317013 Phase 1 CBD
213 Comparison of Skeletal and Mineral Metabolism Responses in Healthy African-Americans and Caucasians Using a Continuous Seven-Day Parathyroid Hormone (PTH) or Parathyroid Hormone-related Protein (PTHrP) Infusion Withdrawn NCT01333267 Phase 1 Parathyroid Hormone-related Protein (1-36);parathyroid hormone (1-34);PTH (1-34) and PTHrP (1-36)
214 Develop and Implement Methods for Diagnostic and Treatment of Hormonal Disorders in Patients With Chronic Kidney Disease Unknown status NCT04439747
215 BaSEIB Clinical Trial - Bariatric Surgery and Exercise Intervention Bone Trial Unknown status NCT02843048
216 Bone Metabolism and Cardiovascular Risk After Kidney Transplant in Adult Patients Unknown status NCT02751099
217 The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 (FGF23 ) in Chronic Kidney Disease Unknown status NCT01002872 Lanthanum Carbonate;Fosrenol;placebo
218 Evaluation of Safety and Efficency of Custom-made Corpectomy Implants: UNiD 3D VBR Unknown status NCT02926391
219 Investigations of the Effect of MK-7 on Bone and Glucose Metabolism and Arterial Calcification Unknown status NCT01922804
220 Study of the Metabolic Profile of Bone in Professional Athletes as a Function of the Kind of Physical Activity Performed Unknown status NCT03386981
221 Molecular Genetic Study of Suspected Cases of Osteogenesis Imperfecta Attending Assiut University Children Hospital Unknown status NCT03169192 Zoledronic Acid
222 How Does Early Age Life Style Affect Bone Strength and General Health at Middle Age? Twenty-Five Year Follow-up Health Status Comparison of a Sedentary Versus Extremely Physically Active Population From an Early Age Unknown status NCT00270608
223 Odense Androgen Study - A Population-Based Study of Androgens, Body Composition, and Muscle Function in 20-29 Year-Old Danish Men Unknown status NCT00150163
224 A Combined Retrospective and Prospective Protocol to Evaluate Vitoss With and Without Bone Marrow Aspirate for Benign Cavitary Lesions Unknown status NCT02165943
225 3D-Printed Personalized Metal Implant in Surgical Treatment of Ankle Bone Defects Unknown status NCT03185286
226 European Implant Cohort Study Unknown status NCT01633619
227 Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study Unknown status NCT03425994 Elvitegravir/Cobicistat/Emtricitabine
228 Open Versus Endoscopic Surgical Management Of Posterior Calcaneal (HAGLUND) Deformity. A Pilot Non Randomized Trial Unknown status NCT03169465
229 Establishing A National Tiered Diagnosis and Treatment System of Osteoporosis in China: A Pilot Study Unknown status NCT03916289
230 Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia Unknown status NCT02652793 Boosted atazanavir;Lamivudine
231 Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Unknown status NCT02556216
232 The Effect of Thiazide and Loop Diuretic on Mineral and Bone Disorder in Chronic Kidney Disease Patients Unknown status NCT03082742 Hydrochlorothiazide;Furosemide
233 Role of NLRP3 Inflammasone and Hypoxia in the Severity of Osteoporosis in Patients With Bronchiectasis Unknown status NCT03467035
234 Observational Prospective Multi-center International Study on the Use of Injectable Calcium Phosphate Cements for the Treatment of Bone Defects in Adults. Unknown status NCT02575352
235 Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease Unknown status NCT03108222
236 Making Accurate Problem Lists in the EHR Unknown status NCT01105923
237 The Effect of Physical Activity on Bone Strength and Immune System in Very Low Birth Weight Infants: is More Really Better?? Unknown status NCT01042639
238 Influence of the Implant-prosthetic Connection in the Marginal Bone Loss and Bacterial Leakage. A Randomized Controlled Trial Unknown status NCT04328051
239 Crestal Bone Loss and Patient Satisfaction of Screw Retained Restoration Using Multi-unit Abutments Versus Intra-oral Luting on Titanium Bases in Implant Supported Complete Overdentures: A Randomized Clinical Trial Unknown status NCT03671668
240 A Taiwan Isoflavone Multicenter Study (TIMS) Unknown status NCT00262184 Soy Isoflavone
241 Metabolic Workup in Patients Suffering From Kidney Stone Disease and Show Osteopenic Bone Changes on Non-contrast CT Scan Unknown status NCT04080973
242 Preventive Fixation of Lower Limbs in Osteogenesis Imperfecta (Brittle Bone Disease) With the Highlight of the Fassier-Duval Unknown status NCT02868294
243 A Randomized Controlled Trial Comparing Two Regimens of Vitamin D Supplementation in Preterm Neonates Unknown status NCT03889717
244 A Double-Blinded Randomized Controlled CER Study of Changes in Bone Mineral Density, Blood Chemistries, Self-Reported Quality of Life and Compliance as a Function of Consuming Micronized Versus Non-micronized Calcium Carbonate Unknown status NCT01857154
245 Fracture and Fall Prevention in Elderly With Osteoporosis: Long-term Follow up Unknown status NCT01844154
246 Randomized Controlled Trial of Classic Yin and Yang Tonic Formula in Osteopenia Unknown status NCT01271647 Yin and Yang tonic granules;placebo
247 Evaluation of Marginal Bone Loss Using Computer Guided Ridge Splitting With Simultaneous Implant Placement Versus Conventional Technique (a Randomized Clinical Trial) Unknown status NCT03989193
248 The Effects of Red Clover Treatment on Bone Tissue Regulation in Postmenopausal Osteopenia. Unknown status NCT02174666
249 Effect of Assisted Exercise on Musculoskeletal System and Growth in Preterm Infants Unknown status NCT03354988
250 Evaluation of Marginal Bone Loss After Immediate Implant Placement in Maxillary Esthetic Zone With and Without Xenograft. Unknown status NCT03397316
251 HIV UPBEAT: Understanding the Pathology of Bone Disease in HIV-infected. A Prospective Cohort Study of HIV-infected Patients and HIV-negative Subjects. Unknown status NCT01778361
252 To Investigate the Efficacy and Mechanism of ZBP Powder Product in the Treatment of Osteopenia in Patients With Pain. Unknown status NCT03245710
253 Use Dual-energy X-ray Absorptiometry and Quantitative Microradiography to Predict the Periprosthetic Bone Loss in Distal Femur After Total Knee Arthroplasty Unknown status NCT01618149
254 To Investigate the Bone and Muscle Abnormalities in Patients With Chronic Kidney Disease Compared to Healthy Volunteers With MRI Unknown status NCT04564924
255 Effect of Mechanical Loading on Radius Bone Density and Microarchitecture in Primary Hyperparathyroidism Completed NCT01571843
256 The Effect of Potassium Bicarbonate on Bone and the Immune System During 21 Days of 6° Head- Down- Tilt Bedrest (HDT- Bedrest) Completed NCT01509456
257 A Prospective Cohort Pilot Study of Bone Metabolism in Lactating and Non-lactating Postpartum African-American Women and Healthy Non-pregnant African-American Women Completed NCT00785824
258 Bone Disease in Chronic Pancreatitis: A Complex Phenomenon Completed NCT02108509
259 Clindamycin-Rifampin Interactions: Effect of Rifampin's Enzyme-induction (Cytochrome P450 3A4/3A5) on Plasma Clindamycin Concentrations, With Clindamycin Given Intravenously and Orally to Treat Bone-and-joint Infections Completed NCT02629770 usual antibiotic treatment
260 Retrospective Study of Bone Infection Due to Campylobacter Spp Completed NCT02884752
261 Pressure Ulcer-associated Osteomyelitis: Retrospective Evaluation of a Two-stage Surgical Strategy (Debridement With Vacuum-assisted Closure Therapy and Reconstruction) With Prolonged Antimicrobial Therapy Completed NCT03010293
262 Patient Activation After DXA Result Notification Completed NCT01507662
263 Clinical and Molecular Manifestations of Human Skeletal Dysplasias and Short Stature Completed NCT00001754
264 Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone(1-34): Effects on Bone Formation Completed NCT00377312 Early Phase 1 Parathyroid Hormone (1-34)
265 Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia. A Randomized, Placebo-controlled, Double Blind Investigation. Completed NCT02731820
266 Gut Microbiome Mediated Effects of Inulin Supplementation on Mineral and Bone Metabolism in Hemodialysis Patients Completed NCT02718885 Early Phase 1
267 A Pilot Study on the Immunopathogenesis of Bone Disease in Older HIV-infected Adults Completed NCT00935935
268 Assessment of Vertebral Fracture Risk Using VFA and Vertebral Strength Assessment With DXA-Finite Element Analysis in Liver Transplant Recipients in Pretransplant Period Completed NCT03811873
269 Bone Biopsy for Histomorphometry and Analysis of Bone Marrow Derived Osteoblast and Osteoclast Progenitors to Explore Mechanisms of Decreased Bone Mineral Density in Depression Completed NCT00001916
270 Effects of Naturally Occurring Silicon in Drinking Water on Bone Metabolism Completed NCT01067508
271 Another Revisional Strategy to Address Severe Late Complications After Previous Biliopancreatic Diversion for Obesity: Major Revision From Standard Biliopancreatic Diversion to Proximal Roux-en-Y Gastric Bypass Completed NCT01041456
272 Effect of Physiotherapy on the Promotion of Bone Mineralization in Preterm Infants Completed NCT04356807
273 Determinants of Bone and Muscle Quality and Strength in Obesity With and Without Diabetes Completed NCT04093856
274 COMBAT 1: COMputerised Bone Age Tool (Phase 1: Feasibility of Using Dual Energy X-ray Absorptiometry for Bone Age Assessment in Children) Completed NCT02617901
275 Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation or the Appliance of Definite Combined Training Program to Counteract Effects of Bed Rest (Acronym: SAG Study) Completed NCT01820702
276 Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study Completed NCT01360099
277 A Prospective Cohort Pilot Study of Bone Metabolism in Lactating and Non-lactating Postpartum Women and Healthy Non-pregnant Women Completed NCT00430417
278 Markers of Parenteral Nutrition (PN) Associated Metabolic Bone Disease in Children on Long-Term PN for Intestinal Failure. Completed NCT01603472
279 Effect of Dried Plum on Bone and Bone Biomarkers in Older Women Completed NCT02325895
280 The Effect of Normalization of Sodium on Bone Markers in Patients With Epilepsy. A Randomized Single-blinded Placebo-controlled Trial. Completed NCT03371199 Sodium chloride;Placebo Oral Tablet
281 Bone Metabolism and Endothelial Function in Patients With Type 2 Diabetes Mellitus and Charcot Foot - an Observational Comparative Study Completed NCT02435329
282 Bone Mass Accrual in Children With Autism Spectrum Disorder Completed NCT03162445
283 Spinal Infection Management With Structural Allograft Completed NCT03265561
284 Endogenous Calcium Stable Isotope Study (eCaSIS): Evaluation of MC-ICP-MS as a Diagnostic Tool for Metabolic Bone Diseases and Disorders of Calcium Metabolism Completed NCT02252679
285 Surgical Field Custom Pack's Efficacy on Soft Tissue Dissecting Time Reduction, on Relative Risks and Materials Wasted, in Patients Undergoing Spine Surgery: Randomized Controlled Trial Completed NCT03050203
286 Procurement of Normal and Abnormal Bone, Dermis and Adipose Tissue for Establishment of Cell Cultures and Tissue Analysis Completed NCT00802607
287 Proposal for Intraoperative Administration of Intravenous Indocyanine Green to Evaluate Position of the Optic Canal, Position of the Internal Carotid Arteries, Tumor Vascularization, and Vessel Encasement in Endoscopic Endonasal Cranial Base Surgery Completed NCT03072186
288 A Prospective Data Collection Study for the Evaluation of Performance and Safety of the Spectrum Dynamics Multi-purpose CZT SPECT Camera Completed NCT03438123
289 Odense Androgen Study in the Elderly Completed NCT00155961
290 Look AHEAD: Action for Health in Diabetes Completed NCT00017953
291 Outcomes of Sleep Disorders in Older Men Completed NCT00070681
292 Short-term Supplementation, Bone Turnover and Antioxidant Status in Postmenopausal Stage: A Placebo Controlled Study. Completed NCT03672513
293 A Prospective Randomized Study Comparing Vitoss Alone Versus Vitoss With Bone Marrow Aspirate in Benign Bone Lesions Completed NCT00147823
294 Evaluation of Adding Virtual Path Planning to the Philips FD20 XperGuide to Reduce Radiation Dose During Image-guided Needle Interventional Procedures. Completed NCT02021071
295 Use of a Radiopaque Localizer Grid and Methylene Blue Staining as an Aid to Reduce Radiation Exposure in Resection Small Femur Lesions Completed NCT02969005
296 Stereophotogrammetry of the Torso in Healthy Individuals and Patients With Scoliosis, Chest Wall Deformations, or Obesity Completed NCT01352949
297 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer Completed NCT01325142
298 A Retrospective Radiological Analysis of Cemento-Osseous Dysplasia Using 3D Imaging Completed NCT04608708
299 Yulin Orthopedics Hospital of Chinese and Western Medicine Completed NCT03129230
300 Impact of the FRAX Assessment on Physician and Patient Treatment Behavior Completed NCT01572766
301 The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome Completed NCT05352373
302 Effect of Soy Phytoestrogens and Acupuncture on Bone Mineral Density in Female Athlete Triad at Adolescence Age Completed NCT04748250
303 Title: Increase Awareness to Osteopenia/Osteoporosis Treatment of Patients With Prostate Cancer, by Bisphosphonate Therapy - Registry. Completed NCT00816452
304 Effect of Full-Body Pulsed Electromagnetic Field Versus Pulsed High Intensity Laser Therapy in the Treatment of Patients With Osteopenia or Osteoporosis Completed NCT05029440
305 Relationship Between Serum 1,25-dihydroxy Vitamin D and Markers of Bone Metabolism in Renal Dysfunction Patients Completed NCT05399251
306 Creatine Supplementation and Bone Mass Completed NCT01163370
307 A Case-control Study of MicroRNAs a Potential Biomarkers for Coronary Artery Calcification (CAC) - An Additional Substudy to Determine the Relationship Between CAC and Bone Mineral Density and Markers of Bone Metabolism Completed NCT01992848
308 Treatment of Osteopenia With Melatonin: Effects on BMD, Muscle Strength and Quality of Life Completed NCT01690000 Melatonin
309 Ninth Dorsal Osteopathic Visceral Manipulation D9 Affects Pancreas Blood Levels Completed NCT03852212
310 Efecto de Dos Tipos de Ejercicio físico Para Prevenir la Osteoporosis en Mujeres Postmenopausicas, un Ensayo Clinico Aleatorizado Completed NCT03091088
311 Effect of Periodontitis on Bone Mineral Density in Postmenopausal Women Completed NCT02628197
312 IGF-1 and Bone Loss in Women With Anorexia Nervosa Completed NCT01406444 rhIGF-1;Risedronate;Placebo
313 Effect of Dried Plum on Bone and Markers of Bone Status in Men Completed NCT04720833
314 An Open, Prospective, Non-randomized, Controlled, Multicenter Study to Evaluate Clinical Outcome of the ASTRA TECH Implant System, OsseoSpeed™ Implant in Women Over 60 Years of Age With Osteoporosis/Osteopenia Completed NCT00745121
315 Genetic Study of Families Affected by Paget's Disease of Bone Completed NCT00747994
316 The Effect of 16 Weeks of Hip Adduction and Abduction Resistance Exercise Training on Strength and Density of the Proximal Femur Completed NCT01228877
317 Supplementation of Vitamin D in Preterm Infants- Monitored Therapy vs Standard Therapy. A Randomized Controlled Trial Completed NCT03087149
318 Pregnancy in Osteogenesis Imperfecta (OI) Registry Completed NCT03072303
319 Impact of Exercise on Sarco-osteopenia in Community Dwelling Men 70 Years and Older. A Randomized Controlled Trial Completed NCT03453463
320 Artificial Intelligence: to Analyse CKD-MBD in Hemodialysis and Cardiovascular Risk Completed NCT02697578
321 Milk and Yogurt vs. Calcium and Vitamin D Supplements for Bone Health of Women Completed NCT01394484
322 Denosumab Protects Bone Loss and Function in Osteopenia Patients With Lumbar Degenerative Diseases After Lumbar Fusion Surgery, a Randomized, Placebo Controlled Trial. Completed NCT05415657 Denosumab;Placebo
323 MUSCLE STRENGTHENING EXERCISES AND GLOBAL STRETCHING: IMPACT ON BALANCE, FEAR OF FALLING AND FUNCTIONAL CAPACITY OF ELDERLY Completed NCT02143674
324 Prospective Exploratory Study:Bone Mineral Density Changes of the Acetabulum After Revision Hip Arthroplasty Using Bone Impaction Grafting Completed NCT02061904
325 Effect of Active Vitamin D and Etelcalcetide on Human Osteoclasts in Patients With Chronic Kidney Disease Completed NCT03527511
326 Addressing Alcohol/HIV Consequences in Substance Dependence - Boston ARCH Cohort Completed NCT01740115
327 Skeletal Physiology Dysregulation in Obesity: The Role of Growth Hormone Completed NCT01724489 Growth hormone;Placebo
328 Assessment of Bone Mineral Content for Preterm Neonates Treated With Caffeine Using Dual Energy X-ray Absorptiometry : an Observational Study Completed NCT03084432
329 Assessing the Efficacy of Herbal Teas on Bone Health in an Osteopenic Population: OsTea Completed NCT03480126
330 Intact Versus Biointact Assays for Longitudinal Assessment of Parathyroid Hormone - The Longitudinal PTH Study Completed NCT03464149
331 Immediate Effect Of Whole-Body Vibration And Walk Over Muscle Strength, Balance And Functional Performance In Elderly People With Osteoporosis And Osteopenia: Clinical Randomized Controlled Trial Completed NCT03448276
332 Translation of ECOS-16 Questionnaire in Urdu Language; Validity and Reliability Analysis in Postmenopausal Women With Osteopenia Completed NCT04873960
333 Effects of the "Spinomed Active" Orthosis on Chronic Back Pain in Women With Osteoporotic Vertebral Bone Fracture and Hyperkyphosis. Completed NCT04854629
334 Effects of High Intensity Multi-Modal Exercise Training on Bone Density and Functional Performance in Postmenopausal Women Completed NCT04653350
335 Cystic Fibrosis Related Bone Disease: the Role of CFTR Completed NCT01549314
336 Portable Bone Ultrasonometer for Osteoporosis Assessment Completed NCT01439139
337 Growth, Health and Development in Children Born Extremely Preterm Completed NCT01150071
338 Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease Completed NCT03626246
339 Effect of Moringa Oleifera on Bone Density in Post-Menopausal Women Completed NCT03026660
340 Pilot Study to Assess the Skeletal Effects of Age-related Changes in Calcium and Vitamin D Metabolism in Men Completed NCT00588874
341 Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults Completed NCT03761979
342 Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women--Aim 2 Completed NCT03688282
343 Prevention of Post Operative Bone Loss in Children Completed NCT00655681 pamidronate
344 Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis: A Pilot Study Completed NCT00490906 Copaxone;Interferon-beta 1a;Interferon-beta 1b
345 Low Magnitude Mechanical Stimulation (LMMS) to Improve Bone Mineral Density (BMD) Completed NCT00396994
346 Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation Completed NCT00302627 Pamidronate;vitamin D;Calcium Carbonate
347 Osteoporosis and COPD (Making of a Database) Completed NCT00231127
348 Alendronate to Prevent Perimenopausal Transition Bone Loss Completed NCT00221312 Fosamax
349 Prevalence of Sarcopenia and Sarcopenic Obesity in Community-dwelling Outpatient Older Adults Completed NCT04122638
350 Losing More Than Just Weight: Bone Loss After Laparoscopic Roux-en-Y Gastric Bypass Completed NCT00975013
351 Phase II Study of Alendronate Sodium in Juvenile Osteoporosis (IND# 60,017)-Post Study Evaluation of Participants From Phase IIa and Phase IIb Clinical Study. Completed NCT00920075 Alendronate (Fosamax)
352 Effects of Whole Body Vibration (WBV) on Musculoskeletal System of Aged Women Completed NCT01982214
353 Bone Mineral Density (BMD) Changes in a Bone Health Plan Using Two Versions of a Bone Health Supplement: A Comparative Effectiveness Research (CER) Study Completed NCT01114685
354 Effect of Protein Supplementation During Weight Loss on Older Adult Bone Health Completed NCT03819478
355 Diurnal Variation in Markers of Mineral and Bone Disease in Chronic Kidney Disease - An Observational Study Completed NCT03698422
356 Optimal Management of Older Women With Distal Forearm Fractures Completed NCT00226031
357 Diagnostic Pilot Study of Dual Energy Absorptiometry in the Detection of Osteopenia or Osteoporosis in Patients With Thalassemia Major Completed NCT00006138
358 Effect on Bone Biomarkers and Bone Mineral Density and Tolerability of Calcium and Vitamin D Supplementation With and Without Collagen Peptides in Postmenopausal Women With Osteopenia Completed NCT03999775
359 Rare Diseases Clinical Research Network Brittle Bone Disorders Consortium Osteogenesis Imperfecta (OI) Quality of Life Survey Pilot Project 2 Completed NCT02793063
360 A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Ginseng Extract on Improvement of Bone Metabolism in Menopausal Women Completed NCT02763280
361 Efficacy of Plyometrics to Increase Bone Mass in Men With Osteopenia Completed NCT00572104
362 Use of an Occlusive Skin Closure System May Reduce Post-operative Wound Drainage After Tumor Arthroplasty of the Hip Completed NCT03746717
363 Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Healthy Children and Adolescent Completed NCT03709381 Early Phase 1 Low Dose Cosyntropin (ACTH) stimulation test;High Dose Cosyntropin (ACTH) stimulation test
364 Heart Failure and Early Stage Chronic Kidney Disease -Mineral Bone Disorder : the Importance of the New Biomarkers Completed NCT03307707
365 A Model for Delivering Strength Training and Nutrition Education for Older Adults (MoveStrong): A Pilot Randomized Controlled Trial Completed NCT04037436
366 A Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of Lifenol in Improving Bone Status in Postmenopausal Osteopenic Women Completed NCT04004013
367 Temporomandibular Disorders in Climacteric Women: Pain Sensibility, Risk Posed by Systemic Bone Mass and Diagnostic Made by RDC/TMD Compared to MRI (3.0 Tesla) Completed NCT01029210
368 Effect of HIV Infection and HAART on Bone Homeostasis Completed NCT01020045
369 Mineral and Bone Disorders Outcomes Study for Japanese Chronic Kidney Disease Stage 5D Patients (MBD-5D) Completed NCT00995163
370 Wiser Choices In Osteoporosis Choice II Completed NCT00949611
371 Prevalence of Osteosarcopenic Obesity in Older Community-dwelling Adults in Turkey Completed NCT04288401
372 A Preliminary Study of Bone Density Measurements in Neonates Using the Sunlight Omnisense 7000P Ultrasound Bone Sonometer Completed NCT00631397
373 Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy Completed NCT00436917 zoledronic acid
374 Use of 18F-Fluoride Positron Emission Tomography in the Assessment and Evaluation of Therapy in Monostotic Paget's Disease of Bone Completed NCT00306046 Bisphosphonate treatment
375 Changes in Bone Density, Radiographic Texture Analysis and Bone Turnover During Two Years of Antiresorptive Therapy for Postmenopausal Osteoporosis Completed NCT00145977 Alendronate
376 Osteopenia and Osteoporosis in HIV Infection. Prospective BMD Measurement in Antiretroviral (ARV) Treated and Untreated HIV-1 Infected Patients Completed NCT00146094
377 Bone Regeneration Using Bone Marrow Stromal Cells Completed NCT00001391
378 Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins Completed NCT04206033
379 Osteofibrous Dysplasia (Kempson-Campanacci's Disease): Long Term Follow-up Study on Natural History, Results of Treatment and Relationship With Adamantinoma Completed NCT04104763
380 Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health Completed NCT01053481 Early Phase 1
381 A Cross-sectional, Comparative, Multi-center Study to Investigate the Effect of Topiramate Monotherapy on Markers of Bone Mineral Metabolism and Bone Mineral Density in Premenopausal Women With Epilepsy Completed NCT01030094 Topiramate;Carbamazepine;Valproic acid;Normal control
382 A Single-Center, Non-interventional Substudy of ALX-HPP-502 to Assess Functional Natural History Data of Patients With Juvenile Historical Controls in ENB-006-09 Completed NCT02235493
383 "Levels of RANKL and OPG in Gingival Crevicular Fluid of Patients With Post-menopausal Osteoporosis / Osteopenia and Periodontal Disease." Completed NCT02184962
384 Effects of Vitamin D Supplementation in Muscle Strength and Postural Balance Training in Vulnerable Elderly Women Completed NCT03367585
385 Prevalence of Morphologic and Metabolic Abnormalities in Vertically HIV-Infected and Uninfected Children and Youth Completed NCT00069004
386 The Effectiveness of Collaborative Care With Smart Health Management Program for Patients With Chronic Illness: Randomized Controlled Trial Completed NCT03294057
387 Prevalence of Gaucher Among Patients With Osteopenia/Osteoporosis Completed NCT02785744
388 Sport and Prevention of Bone Resorption Completed NCT04942691
389 Controlled Split Mouth Study of Effect of Orthodontic and Guided Bone Regeneration on Angular Bone Loss of Over-erupted Tooth Completed NCT05371418
390 Radiological, Biological, Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density Completed NCT01250314
391 Effects of SHR-1222 on Vascular Inflammatory Factors in Patients With Low Bone Mass Completed NCT03898024 SHR-1222;Placebo
392 Markers of Bone Status in Diabetes Mellitus (Type 1 and Type 2) Completed NCT01870557
393 Olive Oil Polyphenols, Vitamin D and Docosahexaenoic Acid (DHA) Synergistic Effects on Locomotor Function Completed NCT01828944
394 Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer Completed NCT01277562
395 Effects of an Optimized 13-month Physical Exercise on (Early)-Postmenopausal Risk Factors in Women With Osteopenia and Osteoporosis (Actlife) Completed NCT03959995
396 Effect of Whole-Body Vibration on Plasma Sclerostin Level in Healthy Young Adult Women Completed NCT01310335
397 Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer in Real World Clinical Settings in Greece Completed NCT01298362 Aromatase Inhibitors;Chemotherapy
398 Hormonal and Bone Turnover Marker Response to an Acute Bout of Resistance or Plyometric Exercise Completed NCT00572871
399 The Effect of Daily Exercise Program on Bone Mineral Density and Cortisol Level in Preterm Infants With Very Low Birth Weight: A Randomized Controlled Trial Completed NCT03773679
400 Safety Profile and Bone Efficacy of the Phytoestrogen Genistein in a Cohort of Osteopenic, Postmenopausal Women After Three Years of Treatment: a Follow-up Study Completed NCT00626769
401 The Effects of Bovine Colostrum in Bone Metabolism in Humans Completed NCT04040010
402 A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study Aiming to Evaluate the Efficacy on BMD and Safety of a Probiotic Product in a Population of Healthy Women in Early Post-menopausal Phase, During an Intervention Period of 12 Months Completed NCT02722980
403 Vitamin D Deficiency in Elderly African American Women in Central Texas Completed NCT01971411 Calcium 500mg with 200 IU Vitamin D - 2 tablets daily
404 Effect of Intake of Protein High in Ketogenic Amino Acids (e.g. Leucine) in Elderly Osteopenic Patients. Implications for Muscle, Bone , Metabolism, and Physical Function. Completed NCT01900548
405 Effect of a Wii Fit Intervention on Balance, Muscular Fitness, and Bone Health in Middle-aged Women Completed NCT01897467
406 Dose-Dependent Effects of Jumping on Bone Health in Premenopausal Women Completed NCT03413540
407 A Two-center Phase II, Non-randomized Study of MRgFUS Versus EBRT in Patients With Metastatic Non-spinal Bone Disease: Palliative Strategy for Cancer-Induced Bone Pain Completed NCT03404362
408 Long-term Effect of Electromagnetic Field in Treatment of Patients With Osteopenia or Osteoporosis. A Randomized Placebo-controlled Trial. Completed NCT04608162
409 The Impact of Combination of Aerobic and Resistive Exercise on Activities of Daily Living and Risk of Fall in Osteosarcopenic Patients Completed NCT04526327
410 A Prospective, Multi-Center Study of the IlluminOss® Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease Completed NCT02338492
411 Dried Plums Prevent Inflammation And Improve Bone Health in Osteopenic Men Completed NCT03408119
412 Sarcopenia and Osteoporosis in the Patients With Hemophilia Completed NCT04535180
413 "Bone Density and Calcitropic Hormones During Lactation in African-American and Caucasian Women" Completed NCT01630629
414 Reliability and Validity Study of the Facilitators and Barriers Exercise Questionnaire Completed NCT03125590
415 Characterization of Bone Architectural Parameters Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Post-menopausal Women Affected With Primary Hyperparathyroidism Completed NCT02539498
416 The Effect of Lactobacillus Reuteri ATCC PTA 6475 on Volumetric Bone Mineral Density in Patients With Osteopenia Completed NCT02422082
417 A Prospective, Multi-Center Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease Completed NCT02373904
418 An Investigation of the the Effect of Nutrient Support, or Nutrient Plus Physical Activity on Musculoskeletal Health and Function in Men and Women Aged 55 to 70 Years Completed NCT02529124
419 Nutritional Deficiencies Preventive Treatment Prior to Laparoscopic Sleeve Gastrectomy: Controlled Clinical Study Completed NCT02483026
420 Effect of Vitamin D3 Supplementation on Cardiometabolic Risk Factors in a Cohort of Overweight and Obese Adults in the United Kingdom (UK) Completed NCT02359214
421 Effects of Standing on Non-Ambulatory Children With Neuromuscular Conditions Completed NCT02428673
422 Effects of a 3-month Weight-bearing and Resistance Exercise Training on Circulating Osteoprogenitor Cells and Bone Formation Markers in Postmenopausal Women With Low Bone Mass. Completed NCT03195517
423 A Multi-Center Observational Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate (BONDORAL) Completed NCT02528747
424 Comparative Effects of Moxonidine and Bisoprolol on Bone Metabolism, Vascular and Cellular Markers of Aging, Blood Pressure in Hypertensive Postmenopausal Women (COMPASS) Completed NCT02355821 Moxonidine;Bisoprolol
425 Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016 Completed NCT02534714
426 Prevalence of Osteoporosis in Hemodialysis Patients and Relevance With Renal Bone Disease Completed NCT00308828
427 Comparison of Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) With Skeletal X-Ray and MRI of the Spine for the Assessment of Bone Disease in Multiple Myeloma Completed NCT01829412
428 Early Initiated Individualized Physical Training in Newly Diagnosed Multiple Myeloma Patients; Effects on Physical Function, Physical Activity, Quality of Life, Pain, and Bone Disease. Completed NCT02439112
429 Effect of Maternal Vitamin D Supplementation During Pregnancy on Offspring Bone Mass, Body Composition and Muscle Strength in Early Childhood: Follow-up of a Randomized Controlled Trial Cohort. Completed NCT03537443
430 Development of a New Simplified Thumb Ossification Composite Index (TOCI) and Its Application to Predict Skeletal Maturity and Curve Progression in Idiopathic Scoliosis and Normal Subjects Recruiting NCT03904914
431 Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia Recruiting NCT04018287
432 Vitamin D and Health Outcomes in Preterm Born Population -A Cohort and an Intervention Study of Vitamin D on Health Outcomes of Bones, Teeth, Muscles, Heart, and Lungs in Children and Adults Born Preterm in Northern Finland Recruiting NCT04342078
433 Evaluation of Children With Endocrine and Metabolic-Related Conditions Recruiting NCT02769975
434 Investigations of Bone-Related Connective Tissue Disorders Recruiting NCT00076830
435 A European, Multicentre, Non-comparative, Non-interventional, Prospective Clinical Registry to Evaluate the Clinical Outcome and Safety of the Treatment of Severely Infected Patients With Fosfomycin i.v. Recruiting NCT02979951
436 Evaluation and Management of Metabolic Bone Disease in Kidney Transplant Recipients Recruiting NCT03958409
437 The Impact of Glomerular Disorders on Bone Quality and Strength Recruiting NCT04528446
438 BASUN - Risks for Malnutrition, Metabolic Bone Disease and Impaired Oral Health After Obesity Treatment - Interaction With Gastrointestinal Microbiota, Psychiatric Morbidity and Socioeconomics Recruiting NCT03152617
439 Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks Recruiting NCT03374215
440 Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry Recruiting NCT04536103
441 A Randomised, Single Blind Study Assessing Radiological Outcomes for Massive Segmental Femoral Replacements Using Either Porous Collar or Porous Collar With HA or Porous Collar With HA and Autologous Stem Cells Recruiting NCT03905174
442 Natural History Study of Parathyroid Disorders Recruiting NCT04969926
443 Safety and Feasibility of a Vertebral Body Tethering Technique for Pediatric Idiopathic Scoliosis Recruiting NCT03802656
444 Radiation-free Bone Imaging by Ultrashort Echo Time (UTE) Magnetic Resonance Tomography (MRT) Recruiting NCT03633032
445 Sleep Apnea, Circulation and Metabolism in Acromegaly - Before and After Treatment Recruiting NCT03431727
446 Quantification in Nuclear Medicine: Interest of the in SPECT-CT Scan SUVspect in Thea New Generation of Gamma-cameras With Semiconductor. Data Collection for the Constitution of an Observatory of Scintigraphies Recruiting NCT03414021
447 Osteocalcin in Bone Metabolism and Aging: Effect of Vitamin K Supplementation on Circulating Levels of Osteocalcin, on Glucose and Energy Metabolism and on Muscle Mass and Function Recruiting NCT04669782 Teriparatide
448 A Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Amorphous Calcium Carbonate in Rheumatoid Arthritis Patients With Osteopenia or Osteoporosis Recruiting NCT05443360
449 Phase 1 Study Non-invasive Use Diffuse Optical Spectroscopy Will Measure the Concentrations of Blood, Water, and Lipids (Fats, for Example) in Tissues Recruiting NCT01166854
450 Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition Recruiting NCT04754711
451 Peri-implant Marginal Bone Loss and Implant Failure in Patients With Smoking Habit: a Case Control Study Recruiting NCT05390242
452 Study of the Role of the Induced Membrane in the Reconstruction of Bone Loss in the Limbs Recruiting NCT04883502
453 Study of Blood Monocytes as a Predictive Marker of Cystic Fibrosis-related Bone Disease Recruiting NCT04877223
454 Fully Constrained Acetabular Liner Versus Dual Mobility Hip Joint in the Surgical Treatment of Metastatic Bone Disease of the Hip - A Randomized, Open-Label, Two-Arm, Non-Inferiority Study Evaluating the Post-Operative Hip Dislocation Rate Recruiting NCT05461313
455 A Comparative Observational Study of the Crestal Bone Loss Around Bone Level Versus Tissue Level Implants in Non-compliant Patients With Healthy or Reduced Periodontium After 5-8 Years in Function" Recruiting NCT04942808
456 Effects of Kinect-based Virtual Reality Training on Bone Mineral Density, Fracture Risk, Physical Performance and Quality of Life in Postmenopausal Women With Osteopenia Recruiting NCT04862910
457 Chinese Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Prevalence Survey Recruiting NCT04714918
458 Design and Development of a Novel Food Supplement for Osteoporosis Based on Gut Microbiome Mechanisms: Efficacy and Tolerability Assessment Recruiting NCT05421819
459 4DCT Wrist Biomarkers During Resisted and Unresisted Tasks in Healthy Controls Recruiting NCT04736537
460 Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients: a Prospective Cohort Study Recruiting NCT03937349
461 Assessing the Efficacy of Melatonin and Osteogenic Loading on Bone Health in an Osteopenic Population: MelaOstrong Study Recruiting NCT04233112 Early Phase 1 Melatonin 5 mg;Placebo (plant fiber) for melatonin
462 Role of Osteocytes in Myeloma Bone Disease Recruiting NCT02212262
463 Progression and Etiology of Cortical Porosity in Diabetic Bone Disease Recruiting NCT04208230
464 A Randomized, Double-blind Clinical Trial Investigating the Efficacy of Salmon Bone Meal on Bone Mineral Density Among Perimenopausal Osteopenic Women Recruiting NCT05066477
465 Influence of the Design of the Transmucosal Abutment on the Marginal Periimplant Bone Loss. Randomized Clinical Trial Recruiting NCT04385355
466 Infliximab Proactive Drug Monitoring in the Pediatric IBD Population Recruiting NCT04921670
467 Food Trial Evaluating the Efficacy of SBD111 Versus Placebo for the Clinical Dietary Management of the Metabolic Processes of Osteopenia Recruiting NCT05009875
468 A Prospective Longitudinal Cohort Study to Determine the Incidence of HIV-associated Non-AIDS Conditions in Newly Diagnosed HIV-infected Individuals Initiating Integrase Inhibitor-based and Other Anti-retroviral Regimens Recruiting NCT03483584
469 Characterization of Familial Myopathy and Paget Disease of Bone Recruiting NCT01353430
470 CT-Based Changes in Bone and Marrow Among Patients on Oral Steroids Recruiting NCT04518722
471 Finding the Optimal Resistance Training Intensity For Your Bones: A Randomized Controlled Trial (FORTIFY Bones) Recruiting NCT05541432
472 Lymphatic Anomalies Registry for the Assessment of Outcome Data Recruiting NCT02399527
473 Marginal Bone Loss in Single Implant Restaurations With Three Different Methods Recruiting NCT05301400
474 A Prospective, Cohort, and Observational Study of the Effect of Integrated Diagnosis and Treatment of Chronic Kidney Disease (CKD) on Clinical Outcomes in Real World Clinical Practice Recruiting NCT05242055
475 Evaluation of the Stability of Implants Placed in Low Quality Bone Following The Use of Osseodensification Technique Versus Ridge Expanders: Randomized Clinical Trial Recruiting NCT05330546
476 Prediction of IBD Disease Activity in Individual Patients Based on PROMs and Clinical Data Recruiting NCT05578768
477 Genetic Analysis to Predict the Development of Paget's Disease Recruiting NCT05309954
478 A Prospective Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Pelvis From Metastatic Bone Disease or Geriatric Pelvic Fractures Recruiting NCT04842266
479 Rare Diseases Clinical Research Network Brittle Bone Disease Consortium Longitudinal Study of Osteogenesis Imperfecta Recruiting NCT02432625
480 Characterization of Intra-osseous Vascular Response With Ultrasound Imaging on Healthy Volunteers Active, not recruiting NCT04396288
481 Addressing Alcohol/HIV Consequences in Substance Dependence - Boston ARCH Cohort: The 4F Study Active, not recruiting NCT03414411
482 In Silico Clinical Trial Comparing the Reading Accuracy of Doctors and a Deep Learning Algorithm for Detection of Metastatic Bone Disease on Bone Scintigraphy Scans. Active, not recruiting NCT05110430
483 The Natural History of Injury-Related Disuse Osteopenia Active, not recruiting NCT03868085
484 Effects of Exercise on Fracture Risk, Bone Mineral Density and Falls in Postmenopausal Women. The Long-term Erlangen Fitness and Prevention Study. Active, not recruiting NCT01177761
485 Investigation of Pathophysiology of Angiogenesis and Osteogenesis in Paget's Disease of Bone Active, not recruiting NCT02802384
486 Assessing Calcium Balance in Children With Chronic Kidney Disease to Optimise Treatment Strategies Active, not recruiting NCT03285854
487 Evaluation of the Spry Belt for Improving Bone Quality Active, not recruiting NCT03986203
488 Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease Active, not recruiting NCT04019379
489 Bone Health and Vitamin D Status in Thai HIV-1 Infected and Uninfected Adults (A Substudy of TNT-HIV 003: Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study) Active, not recruiting NCT01634607
490 Assessment of Metabolic Bone Disease of Prematurity Using an Acoustic Method Enrolling by invitation NCT04752098
491 Evaluation of Stability, Marginal Bone Loss and Occlusal Load Analysis of Customized Posterior Hybrid PEEK Abutments Supported by Short Implants Enrolling by invitation NCT04972240
492 Influence of Z Shaped Incisions on Healing and Interproximal Bone Loss in Comparison With Conventional Sulcular Incisions (H Shaped) in Implant Surgery Under Magnification: A Randomized Clinical Trial Enrolling by invitation NCT04195841
493 Fractures and Bone Disease in Living Kidney Donors Enrolling by invitation NCT04810884
494 Effects of DHEA and Exercise on Bone Marrow Fat in Postmenopausal Women Enrolling by invitation NCT05316272
495 Survey of Sarcopenia and Osteopenia in Individuals With Cerebral Palsy and Examination of Influences After Botulinum Neurotoxin Type A Injection Enrolling by invitation NCT05207124
496 EFFECT OF FLOW RESTRICTION ON BONE QUALITY WITHIN A MULTICOMPONENT EXERCISE PROGRAM FOR OLDER WOMEN WITH OSTEOPOROSIS. SINGLE-BLIND CLINICAL TRIAL. Not yet recruiting NCT04760145
497 Efficacy and Safety of Calcium From Fish Bone in Volunteers With Osteopenia Not yet recruiting NCT05381168
498 Intervention Study of Different Anti-osteoporpsis Intervention Strategies in Patients With Osteopenia and Osteoporosis Not yet recruiting NCT04719572
499 Development of Effective Resources for Phosphate Education for Children and Families With Chronic Kidney Disease: Hearing the Patient Voice Not yet recruiting NCT05439980
500 Pilot Study On Pulsed Electromagnetic Field Therapy For Osteosarcopenia Not yet recruiting NCT05043480
501 European Transplant Registry of Senior Renal Transplant Recipients Receiving Initial Immunosuppression With Tacrolimus Once Daily, Mycophenolate and Steroids Not yet recruiting NCT02558452 Tacrolimus once daily (Advagraf)
502 Efficacy of a Single Infusion of Zoledronic Acid to Mitigate the Rebound Effect of Rapid Bone Loss Following Denosumab Treatment Discontinuation Not yet recruiting NCT05405894 Zoledronic acid
503 Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis Not yet recruiting NCT05060380
504 Evaluation of Crestal Bone Loss Around Short Dental Implants As Affected By Two Suprastructure Materials Not yet recruiting NCT05066815
505 Menier's Disease - Bone Density Study Not yet recruiting NCT05322538
506 Association Between Low Bone Density, Vertebral Fractures, and Pain in Sickle Cell Disease Not yet recruiting NCT05283148
507 Clinical Deployment and Validation of Rho - An Opportunistic Osteoporosis Screening Software-as-a-Medical Device Not yet recruiting NCT05245851
508 Amount of Correction of Torsional Deformity in Blount's Disease After Coronal Plane Deformity Correction by 8 Plate Hemiepiphysiodesis Not yet recruiting NCT05334862
509 Relation Between Acute Kidney Injury and Mineral Bone Disease Not yet recruiting NCT05548725
510 Calciuric Effect and Cyclic Parenteral Nutrition in Preterm Infants Terminated NCT00711763
511 Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoitic Stem Cell Transplant Recipients Terminated NCT00504218
512 Efficacy of a Human Amniotic Tissue-derived Allograft, NuCel, in Patients Undergoing Posteriolateral Lumbar Fusions for Degenerative Disc Disease Terminated NCT02070484
513 DXA Precision and Accuracy Comparison Study Terminated NCT01530477
514 The Effect of Multi-faceted Intervention on Osteoporosis and Mineral and Bone Disorder (CKD-MBD) Terminated NCT04271605
515 Treatment of Childhood Cancer Therapy-induced Osteopenia in Growth Hormone Deficient Adult Survivors: Does Bisphosphonate Treatment Improve Bone Mineral Density? Terminated NCT00145704 bisphosphonate therapy (risedronate)
516 A Prospective, Non-controlled, Clinical Investigation of the M2a-Magnum™ Hip System Terminated NCT00698347
517 Proton Pump Inhibitor Therapy and Bone Density in Premature Infants Terminated NCT00888017
518 Stem Cell Recruitment in Osteoporosis Therapy Terminated NCT01656629 Teriparatide;Alendronate
519 Cost-Effective Use of Bisphosphonates in Metastatic Bone Disease - A Comparison of Bone Marker Directed Zoledronic Acid Therapy to a Standard Schedule Terminated NCT00458796 zoledronic acid
520 Measurement of Ca Kinetics in Humans With Prostate Cancer-induced Bone Disease Terminated NCT00918645 41 Ca
521 Evaluation of Best Practice Alerts and an Actionable Sidebar in Electronic Health Records in Promoting Bone Densitometry Scans Withdrawn NCT04955652
522 What is the Best Policy to Prevent Osteoporotic Fracture? Withdrawn NCT00173693
523 Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients Withdrawn NCT01612299 Zortress® /Everolimus
524 A Pilot Project to Assess the Feasibility of Integrating a Multidisciplinary Rapid Access Metastatic Bone Disease Program (RAMP) at The Ottawa Hospital Withdrawn NCT03134404

Search NIH Clinical Center for Bone Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


deferoxamine mesylate

Cochrane evidence based reviews: bone diseases

Genetic Tests for Bone Disease

Anatomical Context for Bone Disease

Organs/tissues related to Bone Disease:

MalaCards : Bone, Bone Marrow, Kidney, Breast, Prostate, Skin, Spinal Cord

Publications for Bone Disease

Articles related to Bone Disease:

(showing 17482, show less)
# Title Authors PMID Year
1
Treatment of benign bone lesions with an injectable biphasic bone substitute. 41
36209080 2022
2
Preoperative anemia and deep vein thrombosis in patients with perioperative bone trauma: a cohort study. 41
36217199 2022
3
Ultrasonographic analysis of Langerhans cell histiocytosis in children: a report of 55 cases. 41
36168708 2022
4
Increased EFG- and PDGFalpha-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis. 53 62
20124286 2010
5
[Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease]. 53 62
20416172 2010
6
The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. 53 62
19660583 2010
7
The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases. 53 62
19931437 2010
8
Osteopontin: an effector and an effect of tumor metastasis. 53 62
20205680 2010
9
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. 53 62
19915614 2010
10
Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. 53 62
19862816 2010
11
Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. 53 62
19782692 2010
12
Bone biology and the role of the RANK ligand pathway. 53 62
20128323 2009
13
Serum levels of total-RANKL in multiple myeloma. 53 62
19951882 2009
14
Identification of four novel EXT1 and EXT2 mutations in five Chinese pedigrees with hereditary multiple exostoses. 53 62
19839753 2009
15
Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. 53 62
19587705 2009
16
RUNX2 mutations in Chinese patients with cleidocranial dysplasia. 53 62
19515746 2009
17
Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. 53 62
19201081 2009
18
RANKL inhibition for the management of patients with benign metabolic bone disorders. 53 62
19558335 2009
19
Post-translational Regulation of Runx2 in Bone and Cartilage. 53 62
19734454 2009
20
The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. 53 62
19371798 2009
21
RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. 53 62
19344283 2009
22
Role of RANKL in bone diseases. 53 62
19185505 2009
23
Cathepsin K: a therapeutic target for bone diseases. 53 62
19338743 2009
24
RANK, RANKL and osteoprotegerin in bone biology and disease. 53 62
19468919 2009
25
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. 53 62
19016581 2009
26
Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease. 53 62
19098682 2009
27
Clinical applications of RANK-ligand inhibition. 53 62
19356186 2009
28
1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. 53 62
19449179 2009
29
Action of RANKL and OPG for osteoclastogenesis. 53 62
19191757 2009
30
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. 53 62
18778854 2009
31
Targeting Src signaling in metastatic bone disease. 53 62
18942061 2009
32
Emerging treatments for postmenopausal osteoporosis - focus on denosumab. 53 62
19554095 2009
33
Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption. 53 62
18991786 2008
34
[Long-term steroid therapy in children: is adjunct therapy relevant in nephrotic syndrome?]. 53 62
18951767 2008
35
Vitamin D receptor ligand therapy in chronic kidney disease. 53 62
18826852 2008
36
Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. 53 62
18829534 2008
37
Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells. 53 62
18829486 2008
38
RANKL inhibition in the treatment of bone metastases. 53 62
18685421 2008
39
Nutritional rickets and z scores for height in the United Arab Emirates: to D or not to D? 53 62
18937749 2008
40
Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. 53 62
18369625 2008
41
Molecular effects of the tissue-nonspecific alkaline phosphatase gene polymorphism (787T > C) associated with bone mineral density. 53 62
18724009 2008
42
Idiopathic severe elevation of serum alkaline phosphatase following adult renal transplantation: case reports. 53 62
18675129 2008
43
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. 53 62
18038244 2008
44
Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. 53 62
18312448 2008
45
Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). 53 62
18587716 2008
46
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. 53 62
18294945 2008
47
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. 53 62
18057140 2008
48
A case of lethal hypophosphatasia providing new insights into the perinatal benign form of hypophosphatasia and expression of the ALPL gene. 53 62
17922851 2008
49
RANK ligand as a therapeutic target for bone metastases and multiple myeloma. 53 62
17964729 2008
50
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. 53 62
17728092 2008
51
Bone disease drug discovery: examining the interactions between osteoblast and osteoclast. 53 62
18208371 2008
52
Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. 53 62
17445976 2008
53
Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate[corrected]: an improved method for immunohistochemistry. 53 62
18095073 2008
54
Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. 53 62
17905588 2008
55
[Clinical utility of bone markers in the evaluation and follow-up in patients with neoplastic bone diseases]. 53 62
18323037 2008
56
Influence of RANKL inhibition on immune system in the treatment of bone diseases. 53 62
17920324 2008
57
Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients. 53 62
18404790 2008
58
Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease. 53 62
18045304 2007
59
CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. 53 62
17895323 2007
60
Osteoporosis and inflammation. 53 62
18240539 2007
61
RANKL signaling in bone physiology and cancer. 53 62
18685382 2007
62
Vitamin D insufficiency/deficiency in gastrointestinal disorders. 53 62
18290722 2007
63
Changes of serum bone markers in CAPD and hemodialysis patients. 53 62
19582194 2007
64
[RANKL inhibition as therapy for joint damage]. 53 62
17984581 2007
65
A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. 53 62
17657224 2007
66
[Metabolic bone disease in premature infants and genetic polymorphisms]. 53 62
17921123 2007
67
BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. 53 62
17724140 2007
68
Novel mouse model of autosomal semidominant adult hypophosphatasia has a splice site mutation in the tissue nonspecific alkaline phosphatase gene Akp2. 53 62
17539739 2007
69
Gingival epithelial cell expression of macrophage inflammatory protein-1alpha induced by interleukin-1beta and lipopolysaccharide. 53 62
17668983 2007
70
[Creation of highly potent vitamin D receptor antagonists]. 53 62
17666872 2007
71
Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. 53 62
17606458 2007
72
Interventions for preventing bone disease in kidney transplant recipients. 53 62
17636784 2007
73
Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy. 53 62
17457594 2007
74
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. 53 62
17255354 2007
75
Osteopontin dysregulation and lytic bone lesions in multiple myeloma. 53 62
17044113 2007
76
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. 53 62
17562244 2007
77
Biochemical markers of bone turnover in diagnosis of myeloma bone disease. 53 62
17022050 2007
78
Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. 53 62
17290219 2007
79
Human breast cancer cell lines and tissues express tartrate-resistant acid phosphatase (TRAP). 53 62
17088078 2007
80
The molecular understanding of osteoclast differentiation. 53 62
17098490 2007
81
Advances in Runx2 regulation and its isoforms. 53 62
16901655 2007
82
Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis. 53 62
17259742 2007
83
Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system. 53 62
17652963 2007
84
Histone deacetylase co-repressor complex control of Runx2 and bone formation. 53 62
17725488 2007
85
Multiple myeloma/hypercalcemia. 53 62
17634143 2007
86
[Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases]. 53 62
17211092 2007
87
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. 53 62
17107351 2006
88
FGF23: its role in renal bone disease. 53 62
16932898 2006
89
RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis. 53 62
17002576 2006
90
LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. 53 62